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diseases and antimicrobial resistance.
In 2014, an exceptionally high number of suspected bathing water-borne epide-
mics were reported in different parts of Finland. In three of these epidemics, no-
rovirus was detected both in patient samples and samples taken from bathing 
water or the beach environment. Finland's most extensive epidemic to date due 
to the consumption of unprocessed milk involved Yersinia pseudotuberculosis. 
Several cases of mass exposure to tuberculosis were diagnosed around the count-
ry. In all of them, the index case was a young person from a country with a high 
incidence of tuberculosis. Finland too undertook preparatory measures due to the 
ebola epidemic in West Africa.  
In this report, the most recent data is compared with that of previous years in 
order to highlight long-term changes in the occurrence of infectious diseases. The 
data is compiled from the National Infectious Diseases Register maintained by 
the National Institute for Health and Welfare (THL).
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Introduction
Communicable and infectious diseases have by no 
means been completely overcome. In 2014, we had 
several reminders of this, at home and abroad.
Towards the end of March, the WHO issued the 
first alert concerning an Ebola epidemic in Guinea, 
West Africa (National Institute of Health and Wel-
fare news 25 March 2014). Almost fifty cases were re-
ported and the epidemic seemed to be spreading fur-
ther. Ebola had never occurred in West Africa before. 
At that time, no one knew that the epidemic would 
expand to become the largest ever filovirus epidemic, 
with repercussions spreading out to other countries as 
well as the affected area. When this report was writ-
ten in May 2015, the epidemic was not completely 
over, even though Liberia had been declared Ebola-
free. According to the WHO’s latest situation report, 
the case count was highest in Guinea, Sierra Leone 
and Liberia, where there were almost 27,000 cases al-
together involving over 11,000 deaths. The epidemic 
will have to be completely eradicated over the next 
few months if we are to be certain that it cannot re-
cur, as happened in the early summer of 2014.
The epidemic was met by a massive response: the es-
tablishment of the United Nations Mission for Ebola 
Emergency Response, but only in August after a con-
siderable delay. The reasons for this will continue to 
be investigated for a long time to come. One reason 
for the delay in the WHO’s response was probably 
the reduction in the resources available to the or-
ganisation. During the year, the European Centre for 
Disease Prevention and Control (ECDC) published 
risk assessment reports for the EU area, updated at a 
few weeks’ interval, to supplement WHO’s weekly re-
ports. The EU Health Security Committee convened 
on even a weekly basis to discuss preparedness and 
the situation in various countries.
Preparations for Ebola cases among travellers were 
raised to a new level throughout the EU and pre-
paredness plans were revised in Finland. The Ministry 
of Social Affairs and Health set up an inter-sectoral 
working group to coordinate measures in various sec-
tors. During the summer, the Helsinki and Uusimaa 
Hospital District’s prevention guidelines were dis-
tributed to all hospital districts. Throughout the year 
and in cooperation with various actors, the National 
Institute for Health and Welfare prepared several ad-
ditional sets of detailed instructions for the Ebola 
website on topics such as guidelines for staff protec-
tion. In addition, the National Institute for Health 
and Welfare actively communicated on the status of 
the epidemic in What’s New on Infectious Diseases 
(20 news items) and ensured the availability of Ebola 
virus diagnostics in cooperation with Huslab and the 
national health authorities of Sweden.
Unlike many other EU Member States, no cases prov-
en to be Ebola were diagnosed in Finland. However, 
Finland’s preparedness was tested by one suspected 
case at an airport and one case of illness that met the 
case definition, as well as several less severe suspected 
cases. A few cases of Ebola were diagnosed in the EU, 
all affecting health care professionals who had treated 
patients evacuated from the affected area of West Af-
rica and whose protection was found to be defective 
afterwards. None of these cases resulted in a more 
widespread chain of infections. 
There was also a fair number of events in Finland: 
early in the year, the most widespread Yersinia pseudo-
tuberculosis epidemic was associated with the con-
sumption of unpasteurized milk. At least 39 people 
fell ill after consuming unprocessed milk produced 
on a farm in the Uusimaa region. Very young babies 
were among those affected. This re-ignited the debate 
on the safety of unprocessed milk in large-scale re-
tail, in light of the recent relaxation of restrictions on 
selling unpasteurised milk. Since then, the Finnish 
Food Safety Authority Evira has recommended that 
unprocessed milk be heated before use, because the 
pathogens that easily remain in unpasteurised milk 
can proliferate during refrigeration and cause gastro-
intestinal infections.
More cases exposed to tuberculosis were detected than 
in previous years. In collaboration with the Ministry 
of Social Affairs and Health, the National Institute 
for Health and Welfare (THL) prepared new instruc-
tions on the screening of immigrants for pulmonary 
tuberculosis. These instructions are clearly necessary 
in order to enhance the rapid diagnosis of cases and 
reduce the number of cases exposed. Unfortunately, 
the Act on health services for so-called undocumented 
persons was rejected, in an exceptional manner, dur-
ing the final sessions of Parliament. This Act would 
have enabled the Government to meet municipalities 
halfway in covering the costs of treatment, in cases in 
which such costs cannot be collected from an unin-
sured person. Pursuant to the Communicable Dis-
eases Act, municipalities have a comprehensive obli-
gation to prevent infectious diseases in their area. 
The National Institute for Health and Welfare under-
went an organisational reform, becoming lighter due to 
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the removal of one management tier. Cuts in resources 
throughout the institute resulted in large personnel cuts 
in the new Department of Infectious Disease Surveil-
lance and Control. The Department’s bacteriological 
units were combined and a four or five-year genomics 
project was launched in order to restructure the refer-
ence laboratory’s operations. The Department, and the 
National Institute for Health and Welfare (THL) as a 
whole, must engage in even closer cooperation with a 
range of partners in order to improve the THL’s ser-
vices. In addition, register and statistical data will be 
more extensively opened up to various users. 
EpidEmiological ovErviEw of 
finland 
Of respiratory infections, the 2013–2014 epidemic 
season of influenza A was exceptionally long, but its 
peak was brief. Unfortunately, the influenza vaccina-
tion coverage rate for small children remained low, 
with only 16% of the target group being vaccinated. 
Cases of influenza A were identified in the 0 to 4 age 
groups and among over-75s in particular. It was posi-
tive that fewer influenza A infections were detected in 
men aged 15 to 24 than in the previous year, proba-
bly due to the influenza vaccine being offered to con-
scripts. Cases of influenza B remained relatively few.
Enterovirus cases were considerably more numerous 
than in previous years, most of them being diagnosed 
in the autumn. More than half of the patients were 
children under 10 years of age. In autumn 2014, se-
vere cases of respiratory infections were diagnosed 
in the United States and Canada, caused by a type 
D68 (EV-D68) enterovirus. Most of the patients 
were children and the infection required hospital 
treatment, particularly among asthma sufferers and a 
few other patients who developed polio-like paralysis 
symptoms after the respiratory infection. Special at-
tention was paid to monitoring the incidence of EV-
D68 throughout Europe in the autumn of 2014. In 
Finland, the virus was found in some 20 patients suf-
fering from respiratory infections. No serious cases of 
illness or neurological symptoms appeared, with the 
exception of one case that required intensive care. The 
virus was found in Norway in two patients who dis-
played symptoms of paralysis, and in one in France.
In 2014, almost 80 notifications of suspected cases 
of food poisoning were sent to the register IT system 
known as RYMY, jointly maintained by the National 
Institute for Health and Welfare and the Finnish Food 
Safety Authority Evira. The National Institute for 
Health and Welfare contacted the municipal epidemic 
investigation working group with regard to 24 notifi-
cations. In 2014, the National Institute for Health and 
Welfare participated in the control and investigation 
of 38 international bacterial gastrointestinal epidem-
ics, by providing up-to-date information on the situa-
tion in Finland. Food-borne epidemics were probably 
caused in Finland by e.g. hepatitis A (mixed frozen ber-
ries), EHEC O157:H7 (an unidentified food product) 
and Yersinia pseudotuberculosis (unprocessed milk).
At the year end in 2014, the National Institute for 
Health and Welfare published an extensive report on 
the occurrence and consequences of hepatitis C virus 
infections in Finland in 1995‒2013. New, efficient 
medicines for the treatment of hepatitis C infections 
are raising hopes of the long-term eradication of the 
disease. In addition, the National Institute for Health 
and Welfare investigated several infection clusters de-
tected by reference laboratories and international co-
operation partners.
The number of gonorrhoea infections diagnosed was 
around 20 more than in the previous year. More than 
half of these were of domestic origin, which is ex-
ceptional in comparison with previous years, when 
it was established that most infections had been ac-
quired abroad. The number of syphilis infections was 
also higher, at 50 more than in the previous year, and 
many of them are related to travel in Russia and Es-
tonia. Approximately twenty more HIV infections 
were diagnosed than in the previous year. Most HIV 
infections of Finns through heterosexual contact were 
of foreign origin, Thailand in particular. Almost one 
half of syphilis, gonorrhoea and HIV infections con-
tracted by Finnish men were the result of sexual con-
tact between men. 
An exceptionally high number of epidemics caused 
by bathing water were diagnosed in June‒July. In 
some cases, the pathogen was diagnosed as norovirus. 
Despite the fact that the epidemics were probably not 
directly linked, the exceptionally hot weather condi-
tions were likely to have caused congestion and over-
loading on beaches, which then manifested itself in 
an increasing number of notifications of suspected 
epidemics. These epidemics were extensively covered 
in the mass media.
Helsinki, 29 May 2015
Mika Salminen
Head of Department
Department of Infectious Disease
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Respiratory infections
The 2013–2014 epidemic season for influenza A was exceptionally long and the • 
peak of the epidemic was brief.
Influenza vaccination coverage remained low. Cases of influenza A were • 
particularly found among over-75s and the 0-to-4-year-old age groups. 
The season was weak for influenza B. • 
The autumn’s rhinovirus epidemic partly coincided with the peak of the • 
parainfluenza season in November–December. More than half such infections 
were diagnosed in children under the age of 4.
As expected, the minor RSV winter epidemic of 2013 was followed by a major • 
epidemic that began in January 2014 and continued until June. 
Enterovirus cases were considerably more numerous than in previous years, most • 
of them being diagnosed in the autumn. More than half of patients were children 
under 10 years of age.
The number of whooping cough cases was on a par with 2013, but the number • 
of cases in children under the age of 12 months was higher than usual. One 
unvaccinated baby aged under 3 months died of whooping cough.
Unlike previous years, only two patients who had contracted pneumonia caused • 
by the bacterium Legionella had acquired the infection while travelling abroad. 
In three cases, water in the patient’s home premises proved to be the source of 
infection.
adEnovirus
In 2014, 1,003 confirmed cases of adenovirus infec-
tion were recorded (2013: 704). The highest number 
of cases occurred in the under-5 age group, but numer-
ous cases also came to light in the 5 to 9, 15 to 19 and 
20 to 24 age groups. An increasing number of adeno-
virus cases were identified on two occasions in 2014: 
the first peak occurred in February‒April and the next 
in November‒December (90–148 cases per month). 
The number of cases was lowest in the summer months 
(June‒August, around 50 cases per month). 
More than 50 types of adenovirus are known. Some 
cause respiratory infections, while others cause gas-
trointestinal, eye or other infections. Adenoviruses 
are common pathogens in infants and small children; 
they rarely occur in adults. 
Laboratories have various test methods for detect-
ing adenoviruses in clinical samples. Antigen detec-
tion, virus cultures and PCR are sensitive and reliable 
methods used in specialised virus laboratories.
influEnza
In the winter of 2014, the epidemic season began 
towards the end of January, peaked in February and 
continued until the end of May. Viruses of the influ-
enza A(H1N1)pdm09 subtype emerged as the epi-
demic dominant virus in the 2013−2014 season, but 
influenza A(H3N2) viruses occurred simultaneously. 
Only individual cases of influenza B infections were 
detected during the season.
Influenza a
In 2014, 6,362 findings of influenza A were reported 
to the National Infectious Diseases Register, almost 
the same number as in the previous year (2013: 6,001). 
National surveillance of influenza virus infections by 
the National Institute for Health and Welfare led to 
the detection of 87 influenza A infections in January–
April 2014, of which 75% were diagnosed as hav-
ing been caused by the influenza A(H1N1)pdm09 
virus. During the epidemic season 2013–2014, both 
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Figure 1. Cases of influenza A by month, and epidemic virus types 2003–2014 (no. of cases).
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influenza A viruses (H1N1pdm09 and H3N2) were 
concurrently in circulation. The first cases of influ-
enza A infections in the 2013–2014 season were re-
ported to the National Infectious Diseases Register in 
October‒November 2013. The number of findings 
increased in December.
Data in the National Infectious Diseases Register 
and from the national influenza surveillance of the 
National Institute for Health and Welfare indicate 
that the epidemic season peaked in February, during 
weeks 6 to 9. The number of cases began to decline 
gradually in May, until only isolated influenza A in-
fections were being reported. The epidemic season 
2013−2014 proved to be longer than the previous 
one, but the peak period was shorter. The number of 
influenza A cases began to increase markedly again in 
November‒December 2014, which indicated an ex-
ceptionally early start to the season 2014–2015.
Influenza A infections were found in all age groups, 
but unlike the previous year, more were identified in 
the over 75 age group (2014: 603 vs. 2013: 361). Al-
though the national influenza vaccination programme 
offers a seasonal influenza vaccination free of charge 
for children in risk groups and healthy children aged 
6 to 35 months, influenza vaccination coverage has 
remained low: for example, at 13% for children aged 
6 to 35 months in the influenza season of 2012–13 
and 16% in the season of 2013–14. In 2014, cases 
of influenza A were reported in the 0 to 4 age group 
(710) in particular. In the 15 to 24 age group, fewer 
influenza A infections were detected in men than in 
the previous year (2013: 348/614 vs. 2014: 157/382). 
The explanation for the low percentage of influenza 
infections in this age group is probably the free influ-
enza vaccination offered to conscripts since autumn 
2012. Vaccination coverage is high among those in 
military service and the influenza viruses that circu-
lated in Finland during the 2013–2014 season were a 
good match for the viruses in the vaccine. 
In recent years, the genetic diversity of both the in-
fluenza A(H1N1)pdm09 and A(H3N2) viruses has 
increased. Several genetic groups were found in both 
influenza A subtypes in 2014. 
Since they appeared, the diversity of A(H1N1)pdm09 
viruses has increased and several genetic groups cir-
culating as epidemics have been identified. Influ-
enza A(H1N1)pdm09 viruses identified during the 
2013–2014 epidemic season represented one of the 
genetic groups commonly circulating in Europe; no 
antigenic differences were detected between this virus 
and the A/California/07/2009 vaccine virus.
The viruses of the influenza A(H3N2) group circu-
lating worldwide comprised two distinct genetic lin-
eages, Perth/16/2009 and Victoria/208/2011, with 
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Figure 2. Cases of influenza B by month, and epidemic virus types 2003–2014 (no. of cases).
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some antigenic differences. In 2012, the occurrence 
of viruses belonging to the Victoria/208/2011 lin-
eage increased and, thereafter, several genetic sub-
groups have formed within the lineage. Almost all 
influenza A(H3N2) viruses found in Finland during 
the epidemic season 2013−2014 represented two ge-
netic groups of the Victoria/207/2011 lineage, which 
commonly circulates in Europe. Towards the end of 
the season, after the WHO’s vaccine recommenda-
tion for the northern hemisphere, transformed vi-
ruses belonging to both genetic groups were de-
tected. These new types of viruses were found in a 
few countries in Europe, even in Finland, and in the 
United States. Some antigenic differences from the 
A/Texas/50/2012 vaccine virus have been detected in 
the transformed viruses. 
Influenza b
The year 2014 was weak in terms of influenza B virus 
infections. A total of 775 cases of influenza B were 
reported to the National Infectious Diseases Register 
in 2014 (2013: 1652). The incidence of influenza B 
infections during the winter and spring (January to 
May) was low but steady. The incidence increased to-
wards the end of the year in December. Influenza B 
infections were diagnosed in all age groups.
Of the two influenza B virus lineages that have circu-
lated the world in recent seasons, the occurrence of 
the Yamagata lineage has increased. In the 2013−2014 
epidemic season, only individual cases of Yamagata 
lineage viruses were diagnosed in Finland.
Vaccine for the epidemic season 2014–2015
Based on reports on the influenza A and B epidemic 
viruses circulating the world, the WHO did not rec-
ommend a change to the vaccination composition 
in the northern hemisphere for the epidemic season 
2014–2015. The recommended virus component for 
influenza A(H3N2) was A/Texas/50/2012 and for 
A(H1N1)pdm09 it was A/California/07/2009. For 
influenza B, the recommended component was the B/
Massachusetts/02/2012 virus of the Yamagata lineage.
season 2014–2015
The first cases of influenza A and B infections were 
reported in November and December 2014. The 
2014−2015 season started in December, clearly ear-
lier than in previous seasons. By mid-March, no peak 
had occurred as in previous seasons. Instead, a steadi-
ly high number of influenza A infections was detect-
ed. The number of influenza B infections began to 
increase in February.
During the season, influenza A(H3N2) viruses that 
had transformed from the vaccine virus were domi-
nant and only sporadic cases of influenza A(H1N1)
pdm09 infections were diagnosed. These proved sim-
ilar to the vaccine virus. Like the vaccine virus, influ-
enza B viruses were of the Yamagata lineage. Some of 
the viruses were analysed in more detail and found to 
differ from the influenza B vaccine virus. 
At the end of February 2015, the WHO issued a 
new vaccine recommendation for the northern hemi-
10
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sphere 2015–2016 epidemic season, based on the 
then current epidemic situation, recommending that 
the influenza A(H3N2) virus component be replaced 
with the A/Switzerland/9715293/2013 virus, corre-
sponding to the new transformed A(H3N2) viruses 
circulating as an epidemic. The influenza A(H1N1)
pdm09 component remained unchanged as the A/
California/07/2009 virus. The recommendation 
for the influenza B component was to change it to 
B/Phuket/3073/2013, which is also a virus of the 
Yamagata lineage but differs somewhat in antigeni-
cal terms from the previous Yamagata lineage compo-
nent in the vaccine. 
parainfluEnza
Parainfluenza viruses are grouped under one head-
ing in the National Infectious Diseases Register, 
even though laboratories usually differentiate be-
tween parainfluenza viruses 1, 2, 3 and 4. In 2014, 
556 parainfluenza infections were confirmed (2013: 
433), most of them in the 0 to 4 age group. Based 
on the number of cases, two separate epidemic peaks 
were detected in 2014. The first epidemic, which was 
smaller, occurred at the turn of the year 2013 and 
2014 (71 cases in December 2013 and 61 in January 
2014) and the second one at the end of the year 2014, 
in November‒December (a total of 209 cases).
Parainfluenza virus infections are found in patients of 
all age groups. A child’s first parainfluenza infections 
can lead to a severe condition that may require hos-
pitalisation. In an older child or an adult, the symp-
toms of a parainfluenza infection are typically much 
milder. They often present as an ordinary upper respi-
ratory tract infection and do not necessarily require 
laboratory diagnostics. In special groups, however, 
such as immune deficiency patients, parainfluenza vi-
ruses may cause severe symptoms. Almost every year, 
parainfluenza virus type 3 causes minor epidemics in 
the summer and autumn, whereas type 1 and 2 vi-
ruses do not cause epidemics every year. 
rhinovirus
In 2014, 728 confirmed cases of rhinovirus infection 
were recorded (2013: 449). The numbers were highest 
from September to December (72–110 per month), 
while at other times, rhinovirus infections occurred at 
a steady rate every month (35–56 per month). More 
than 50% of these infections were diagnosed in chil-
dren under the age of 4.
More than 150 types of rhinovirus are known. They 
are the most common cause of mild respiratory in-
fections. Rhinovirus infections are most common in 
young children, but are present in all age groups. In 
autumn 2014, the rhinovirus epidemic partly coin-
cided with the peak of the parainfluenza season in 
November‒December. Since August 2013, rhinovi-
ruses have been included in the surveillance of re-
spiratory virus infections conducted by the National 
Institute for Health and Welfare (THL), which may 
partly contribute to the increase in the number of 
cases in 2013 and 2014. Laboratories use the PCR 
test to detect rhinoviruses in clinical samples. This 
test is extremely sensitive and reliable. Specialised vi-
rus laboratories are also able to culture rhinoviruses.
rsv
In 2014, 2,863 cases of RSV confirmed by laboratory 
tests were reported to the National Infectious Dis-
eases Register (2013: 1,990). On the basis of long-
term surveillance, a major RSV epidemic is observed 
in Finland every other winter, often starting in No-
vember–December. In addition, a minor epidemic 
occurs between the major ones. As expected, the mi-
nor winter epidemic of 2013 was followed by a major 
epidemic that began in January 2014 and continued 
until June. Individual cases of RSV infection were di-
agnosed during the summer and in the latter part of 
the year.
The majority (over 80%) of RSV infections are veri-
fied by laboratory testing in patients in the 0 to 4 
age group, but RSV infections can occur in all age 
groups. However, cases requiring hospitalisation and 
laboratory diagnostics mainly involve infants and 
small children. In hospital conditions, RSV is easily 
transmitted between patients. Reliable quick tests for 
RSV diagnostics used in hospitals, outpatient clinics 
and health centres make it easier to identify RSV in-
fections and prevent further transmission. Specialised 
virus laboratories increasingly use genetic replication 
methods for diagnosing RSV.
EntErovirus
In autumn 2014, severe cases of respiratory infection 
were diagnosed in the United States and Canada, 
caused by the type D68 (EV-D68) enterovirus. Most 
of the affected patients were children who required 
hospitalisation, particularly among asthma sufferers. 
EV-D68 was also identified in a few patients who 
developed polio-like paralysis symptoms after the re-
spiratory infection. In the autumn of 2014, special 
attention was paid to monitoring the incidence of 
EV-D68 in Finland as in other parts of Europe. In 
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Figure 3. Cases of RSV per month, 2003–2014 (no. of cases).
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Finland, the virus was diagnosed in some 20 patients 
with a respiratory infection, some of them children 
and others adults. No serious cases of illness or neu-
rological symptoms appeared, with the exception of 
one case that required intensive care. Respiratory in-
fections caused by EV-D68 were diagnosed in most 
European countries. In addition, the EV-D68 vi-
rus was found in Norway in two patients exhibiting 
symptoms of paralysis, and in one in France.
In 2014, 298 cases of enterovirus infection were re-
ported to the National Infectious Diseases Register, 
considerably more than in 2013 (184) or 2012 (166). 
Of the cases, 154 (52%) were men and more than 
half (51%) in children under the age of 10. Most 
cases of enterovirus were found in the autumn, with 
72% being diagnosed in August–November. 
Enteroviruses cause not only upper respiratory tract 
infections but conditions such as meningitis, myo-
carditis, hand, foot and mouth disease and other 
types of eczema. Enterovirus diagnostics is based on 
virus cultures or increasingly on the PCR method. 
Virus typing is performed on the basis of antibodies 
or molecular genetics. 
whooping cough
In 2014, the number of whooping cough cases re-
ported to the National Infectious Diseases Register 
totalled 205 (3.78/100,000), similar to 2013 (192; 
3.6/100,000). As before, the cases were most com-
mon in the 0 to 14 age group, with seventeen cases 
in patients under 12 months of age and nine of them 
under 3 months of age, more than in the previous 
year. The only fatality due to whooping cough was the 
case of an unvaccinated baby under 3 months of age. 
The diagnosis of most patients aged under 12 months 
was principally based on a PCR test (14, 78%). In 
six cases, diagnosis was confirmed through a positive 
culture (22%), and for most patients of other ages, 
the diagnosis was made on the basis of antibody test-
ing (173; 84%). 
In 2014, all 12 strains of B. pertussis produced pert-
actin, one of the components of the vaccine used in 
Finland. In addition, one strain in a 5-year-old child 
was confirmed as B. parapertussis.
As previously, the incidence of whooping cough varied 
considerably by hospital district (0–11.6/100,000). 
The incidence was highest in the Kainuu Hospital 
District, while no cases were diagnosed in the Keski-
Pohja Hospital District. 
Choosing an optimum vaccination strategy for 
whooping cough is challenging, as the available cell-
free vaccines are incomplete in terms of their effi-
ciency and duration. A booster for six-year-olds was 
added to the national vaccination programme in Fin-
land in 2003. In 2005, the whole-cell vaccine was 
replaced with a cell-free combination vaccine con-
taining the Bordetella pertussis antigen for children 
in the age groups covered by child care clinics. Until 
2007, adolescent vaccinations were given between the 
ages of 11 and 13. Since 2009, the recommendation 
has been to vaccinate adolescents at the age of 14 to 
12
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Figure 5. Cases of Mycoplasma pneumoniae and Chlamydia pneumoniae per month, 2003–2014 (no. of cases).
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Figure 4. Cases of whooping cough in children’s and young adults’ age groups 2003–2014 (no. of cases).
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15, i.e. beginning in the 8th grade of comprehensive 
school. Due to this transition, very few of these vac-
cinations were administered between 2009 and 2011. 
This created a temporarily less well protected cohort 
in adolescent age groups. Illness in infancy indicates 
insufficient herd immunity. A whooping cough vac-
cine for conscripts beginning their military service 
was added to the Finnish Defence Forces’ vaccination 
programme in summer 2012. 
So far, Finland has been spared the extensive whoop-
ing cough epidemic that generated more than 40,000 
cases in the United States and almost 10,000 cases 
in the UK during 2012. In 2012, the year the epi-
demic occurred, on the basis of an extensive strain 
collection in the United States it was discovered that 
60% of B.pertussis strains did not produce pertactin. 
Both countries initiated a whooping cough vacci-
nation campaign for pregnant women, resulting in 
a significant reduction in the number of whooping 
cough cases in young infants. With respect to Fin-
land’s neighbouring countries, in Sweden the number 
of whooping cough cases almost tripled in 2014. 
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chlamydia pnEumoniaE
In 2014, 205 cases of Chlamydia pneumoniae were 
reported based on laboratory verification, mainly an-
tibody testing. The highest incidence was reported in 
the hospital districts of Satakunta, East Savo, Länsi-
Pohja and Lapland, while the number of cases was 
highest in the Helsinki and Uusimaa Hospital Dis-
trict (67). Although the number of reported infec-
tions was highest among 5 to 19-year-olds, cases can 
be found in all age groups. This can probably be ex-
plained by the fact that primary infections most often 
occur in that age group. Such primary infections of-
ten stimulate an IgM response, facilitating measure-
ment in a single serum sample. The infection can be 
diagnosed even more definitively on the basis of a sig-
nificant change in IgG levels in paired serum samples. 
It is also possible to detect nucleic acid in a sample 
from the respiratory tract.
lEgionElla
In 2014, 22 cases of legionellosis were reported. 
Three of these were diagnosed on the basis of two 
laboratory tests; nine findings were based on the de-
tection of the antigen in urine, two on the isolation 
of the bacterial strain, one on the detection of nucleic 
acid in sputum, and 13 on serological methods. Fur-
ther investigation revealed that the clinical presenta-
tion was consistent with legionella pneumonia in 10 
cases (45%), nine tested positive for the presence of 
the legionella antigen in urine, the bacterial strain 
was isolated in two cases and serological proof was 
found in one case. Unlike in previous years, only two 
persons (2/10, 20%) had travelled abroad before fall-
ing ill (2011‒2013: 77‒100%). Eight patients were 
male and their age varied between 49 and 80. Of the 
cases found positive in the culture, one belonged to 
L. pneumophila serogroup 1 and the other to L. pneu-
mophila serogroup 6.
In the case of seven of the patients who had contract-
ed pneumonia, various premises (home, hospital, 
workplace) were investigated in more detail as pos-
sible sources of infection. A clinical legionella strain 
was available for one patient, in whose detached 
house the same Legionella pneumophila serogroup 
1 sequence type (ST 1) was detected in the shower 
(530,000 cfu/l) and jacuzzi (45 cfu/l). In addition, 
Legionella pneumophila serogroup 1 was found in the 
homes of two other patients (terraced house 1,500 
cfu/l and block of flats 45,000 cfu/l) . In these three 
homes, which were the likely source of infection, 
hot water temperatures were measured and found to 
fall below recommendations and regulations (lowest 
temperatures at 50‒52°C). Legionellas were there-
fore prevented e.g. by permanently raising the tem-
perature of hot water and by rinsing the water out-
lets more abundantly than usual with the water as 
hot as possible. Legionellas were not detected in the 
homes or workplaces of the four other patients. For 
one of them, the potential source of infection was en-
countered when travelling abroad, but the remaining 
six patients whose source of infection was examined 
more thoroughly had no travel history. The thresh-
old for measures requiring cleaning is >1,000 cfu/l 
according to the European guideline for legionella, 
which is followed in Finland.
Accommodation data related to all of the patients 
who fell ill abroad was reported to ELDSNET (Eu-
ropean Legionnaires’ Disease Surveillance Network), 
which collects data on travel-related cases of legionel-
losis. European surveillance indicates that the major-
ity (ca. 60-70%) of cases are of community origin, 
some 20% are associated with travel and fewer than 
10% originate in hospitals. In Finland, cases of legio-
nellosis are traditionally linked with travel. Legionella 
is therefore often ignored as the potential pathogen 
in pneumonia cases of domestic origin, when con-
tracted outside hospitals. 
mycoplasma pnEumoniaE
In 2014, the total number of Mycoplasma pneumoniae 
cases confirmed in laboratory tests was 2,806, having 
exceeded 4,600 in 2012 and 7,800 in 2011. If the oc-
currence of M. pneumoniae cases follows the previous 
pattern, we are now experiencing a 4‒7-year period 
between epidemics and have a few years to wait be-
fore a new winter epidemic occurs. 
As in previous years, the majority of cases (more than 
900) were recorded in the Helsinki and Uusimaa Hos-
pital District. The incidence was still highest in the 
Hospital District of East Savo (>190/100,000). More 
than 60% of the cases were diagnosed in the 5 to 24 
age group, as a diagnosis confirmed by a laboratory is 
often gained on the basis of the primary infection.
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Gastrointestinal infections
An exceptionally high number of epidemics caused by bathing water were • 
diagnosed in June–July. In some cases, the pathogen was diagnosed as norovirus.
The number of • Clostridium difficile cases has remained at the same level for 
the past five years and regional differences remain considerable. In 2014, more 
sensitive detection methods became more common.
The number of EHEC cases was a third less year-on-year. Approximately one half • 
of the infections were of domestic origin.
Frozen berries were the suspected source of an international epidemic of hepatitis A. • 
Campylobacter is the most common bacterial cause of gastrointestinal infections • 
in Finland. More infections were detected in 2014 than before and one half of 
them were related to travel abroad.
The number of listeria cases reported was equal to that of 2013. More than one • 
half of patients were aged over 75.
The number of salmonella cases was one fifth lower than in the previous year. • 
Almost 80% of infections were of foreign origin.
As in previous years, the number of norovirus cases was highest in January–May.• 
The number of rotavirus infections has remained below 500 since the rotavirus • 
vaccine was introduced to the national vaccination programme in September 
2009.
In the spring, • Yersinia pseudotuberculosis in unprocessed milk caused an 
unusually extensive outbreak.
food- and watEr-bornE 
outbrEaks
From the beginning of 2010, municipal epidemic in-
vestigation working groups have entered notifications 
of suspected food- and water-borne outbreaks into the 
register IT system, jointly maintained by the Nation-
al Institute for Health and Welfare and the Finnish 
Food Safety Authority Evira and known as the RYMY 
information system. In 2014, 77 such notifications 
were entered (2013: 73). The National Institute for 
Health and Welfare (THL) contacted the municipal 
outbreak investigation working group with regard to 
24 notifications. In addition, THL investigated sever-
al infection clusters detected by reference laboratories 
and international cooperation partners. 
The National Institute for Health and Welfare is in-
volved in the Epidemic Intelligence Information Sys-
tem EPIS, coordinated by the European Centre for 
Disease Prevention and Control (ECDC), which, if 
epidemics arise, enables European countries to pro-
vide and gain information on epidemic investigations 
in other countries. In 2014, the National Institute for 
Health and Welfare participated in the control and 
investigation of 38 international bacterial gastrointes-
tinal epidemics by providing up-to-date information 
on the situation in Finland via the system. In turn, 
Finland sent three EPIS queries regarding S. Typh-
imurium (phage type unnamed NST, MLVA 3-15-
NA-NA-0311), EHEC O157:H7 (PT88, sorbitol- 
fermenting, phenotype static) and EHEC O55:H7 
clusters. In one report, coordinated by the ECDC 
and in which Finland participated, meat consumed 
in a restaurant was suspected to be the source of 
monophasic S. Typhimurium infections. The ECDC 
also coordinates the Molecular Surveillance Pilot 
project, in which participating countries send the 
most up-to-date typing data possible to the ECDC 
register in order to facilitate the detection of cross-
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border epidemics. Strains isolated in Finland were 
included in 13 salmonella and four listeria clusters. 
Most of the clusters detected were caused by mono-
phasic S.Typhimurium (7 clusters).
an eHec epidemic caused illness in various 
parts of finland
In January‒February, six people fell ill with an infec-
tion caused by the EHEC O157:H7 (FT 88, stx2, eae, 
hlyA, static phenotype, PFGE type 1.203) strain. A 
similar EHEC bacterial strain was also diagnosed in 
four family members who did not display any symp-
toms. Those who fell ill were aged between 4 and 16, 
from different parts of Finland. Three patients were 
diagnosed with hemolytic uremic syndrome (HUS). 
The cases are connected to the EHEC O157:H7 epi-
demic that began in December 2013. Laboratory 
tests proved the bacterial strain to be identical with 
the EHEC infections detected in spring 2013. The 
source of infection was investigated jointly by the Na-
tional Institute for Health and Welfare (THL) and 
the Finnish Food Safety Authority Evira. The inter-
views conducted did not reveal any specific occasion 
or farm visit that constituted a link between the suf-
ferers, nor did the diets of the families or the shops, 
store chains or restaurants they used. The source of 
the epidemic remained unidentified, but as infec-
tions were diagnosed in different parts of Finland, the 
pathogen most probably originated in a widespread 
food product or other product contaminated by the 
EHEC bacteria. In order to examine the extent of the 
infections, Finland sent an international EPIS query. 
No infections caused by the EHEC strain in question 
had been detected in Europe or the United States. 
frozen berries were the suspected source 
of an international epidemic of hepatitis a
In January‒June, 10 cases of hepatitis A were diag-
nosed in various parts of Finland. They were similar 
in genotype to the virus (HAV IA) that caused the 
HAV epidemic that began in Italy in 2013 and was 
detected in Norway in early 2014. The affected per-
sons had not travelled abroad prior to the onset of 
their symptoms. Moreover, two other IgM positive 
cases of hepatitis A of domestic origin were detected, 
but their samples could not be genotyped. Cases were 
diagnosed in a total of 13 EU/EEA countries, includ-
ing Finland. In Italy, the HAV infections were linked 
with berries in a survey, and a virus identical to the 
patients’ strains was detected in mixed frozen berries 
consumed in the cases in question. In Norway, the 
source of infection was confirmed as a frozen berry 
cake made in Germany. The same cake was distrib-
uted to institutional kitchens in Finland under the 
name ‘queen cake’ until the end of April. Some of the 
interviewed patients remembered having consumed 
a similar cake. After the cake was recalled, no similar 
new cases were detected. 
Finland participated in a multinational study coordi-
nated by the European Centre for Disease Prevention 
and Control (ECDC) regarding the infections diag-
nosed in this country. Based on epidemiological and 
microbiological research, frozen berries are the most 
probable source of infection, but the type or types 
of berries linking the infections could not be identi-
fied. The Finnish Food Safety Authority Evira recom-
mends that frozen berries of foreign origin be heated 
before consumption.
salmonella clusters 
In April‒May, S. Mikawasima, which is susceptible 
to antimicrobials, caused six infections in southern 
and central Finland. These were identical in genotype 
(SMIK11). Mikawasima is a rare serotype in Finland. 
The same genotype was last reported in 2008. How-
ever, a different genotype of Mikawasima (SMIK3) 
caused a cluster of infections among the staff of a 
cruise vessel in November 2008 and another among 
bed-ridden patients of a health centre in central Fin-
land in November‒December 2010. 
In May–June, a multiresistant S. Typhimurium (PT 
U302, MLVA 2-12-19-16-0212) made four persons 
ill in eastern Finland. The MLVA type in question 
is rare in Finland. A visit to a farm was the connect-
ing factor between the patients and a multiresistant 
(ACSSuTG) S. Typhimurium FT U302 strain, with 
MLVA profile 2-12-19-15-0212, was isolated in the 
stool of cattle. Because multiresistant S. Typhimurium 
strains are rare in Finnish agriculture and the MLVA 
profile of the animal only differed from the strains 
isolated from human infections by one repeat unit at 
one MLVA locus, the farm was the suspected source 
of the infections. One patient was also diagnosed 
with an EHEC non-O157 infection, the source of 
which remained unidentified.
In June‒July, a multiresistant (ASSuT) monophasic 
S. Typhimurium FT 120 caused a cluster of 10 in-
fections in various parts of Finland. The strains in 
the cluster comprised two highly similar genotypes 
(MLVA 3-12-17-NA-0211 and 3-12-16-NA-0211). 
The same genotype was simultaneously detected in a 
total of 38 cases in six EU Member States. Analyses 
by ECDC and THL identified meat consumed in a 
restaurant as the suspected source of infection. 
In June‒September, susceptible S. Typhimurium FT 
NST (phage type unnamed), genotype MLVA 3-15-
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Figures 6a and 6b. Cases of Clostridium difficile by hospital district, 2008–2014 (no. of cases).
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NA-NA-0311 infections were diagnosed in 21 per-
sons in different parts of Finland. Finland submitted 
an international EPIS query. Responses indicated that 
the infections were only present in Finland. Based on 
interviews with five patients, no specific connecting 
factor was found with respect to the infections. 
epidemics transmitted by bathing water 
and beach environment 
Pursuant to Government decree 1365/2011, notifi-
cations of suspected epidemics transmitted by bath-
ing water have been entered in the register IT system 
for food- and water-borne epidemics (RYMY) since 
the beginning of 2012. In July‒August 2014, an ex-
ceptionally high number of notifications of suspected 
epidemics (15) were entered in the system, originat-
ing in different parts of Finland. Before then, only 
isolated cases of bathing water borne epidemics had 
been registered in the country. Eight of the suspected 
epidemics were classified as having been transmitted 
by bathing water or the beach environment. Based on 
the results of investigation reports by municipalities, 
such assessments are conducted jointly by the Na-
tional Supervisory Authority for Welfare and Health 
(Valvira) and National Institute for Health and Wel-
fare experts. The results for seven of the suspected 
epidemics did not refer to bathing water or the beach 
environment. In the case of three of the epidemics, 
the pathogenic microbe could be identified, since no-
rovirus was found both in the patient samples and 
samples taken from the bathing water or the beach 
environment. In two of the epidemics, adenovirus 
was found in the bathing water but was not detected 
in the patient samples. 
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Valvira and Regional State Administrative Agencies 
guide municipal health protection authorities in con-
trolling the quality of bathing waters. Municipal out-
break investigation working groups submit investiga-
tion reports on epidemics to the RYMY IT system in 
the manner specified by Valvira. The Infectious Dis-
ease Control Unit and the Water and Health Unit of 
the National Institute for Health and Welfare provide 
assistance in the form of consulting and, if necessary, 
coordinate the investigation and prevention of epi-
demics. In order to prevent and investigate bathing 
water borne epidemics, Valvira has sent instructions 
in letter form to health protection authorities with-
in municipalities and Regional State Administrative 
Agencies regarding the 2015 bathing season.
yersinia pseudotuberculosis caused an 
extensive outbreak in unprocessed milk in 
southern finland
In February‒April, the bacterium Yersinia pseudotu-
berculosis in unprocessed milk caused an unusually 
extensive outbreak in Finland. A total of 55 people 
contracted a gastrointestinal infection. The major-
ity of them (51) were from Helsinki and the region 
of Uusimaa. In March, the Porvoo hospital reported 
that it had diagnosed a higher than usual number of 
Yersinia pseudotuberculosis cases. On the basis of in-
depth interviews, the suspected source of infection 
was identified as unprocessed milk from a certain 
producer. This milk was sold in 3-litre containers in 
24 shops in southern Finland. Due to the results of 
the in-depth interviews, the producer voluntarily in-
terrupted the commercial production of unprocessed 
milk and recalled the products in early April. A sur-
vey was conducted to examine typical sources of the 
Yersinia pseudotuberculosis infection and exposure to 
unprocessed milk. Consumption of unprocessed milk 
from the producer in question was established as the 
link to the illness. Microbiological tests revealed Yers-
inia pseudotuberculosis strains, identical to the patients’ 
strains, in the milk filter of the farm’s milking machine 
and a milk sample taken from the refrigerator of one 
patient. The National Institute for Health and Wel-
fare and Evira recommend that children, the elderly, 
expectant mothers and persons suffering from a severe 
underlying illness refrain from consuming unheated, 
unprocessed milk. Based on the results of the epi-
demic account, the consumption of unprocessed milk 
cannot be recommended for healthy adults either.
clostridium difficilE
In 2014, of the total of 5,725 cases of Clostridium 
difficile reported to the National Infectious Diseases 
Register, either 5,156 (90%) cases involved a toxin-
producing strain or PCR was the only diagnostic 
method. The number of cases has been similar for the 
last five years (number of cases between 5,724 and 
6,380, of which 4,827–5,401 were toxin positive). 
The slightly higher proportion of women and the 
age distribution also remained unchanged: in 2014, 
women’s proportion was 58%, that of under 15-year-
olds less than 4%, that of under 2-year-olds under 
2% and that of 75 years or older almost 50%. Noti-
fications were submitted by 20 clinical microbiology 
laboratories, the three largest of which accounted for 
50% of the findings. As previously, the regional differ-
ences in incidence were notable (37–206/100, 000). 
This may be due to differences in diagnostic methods, 
the frequency of active sample-taking and/or preven-
tion measures. 
The laboratory methods used changed distinctly in 
2014. The use of more sensitive PCR or other nu-
cleic acid detection methods increased and, for the 
first time, were more popular than antibody testing. 
The proportion of nucleic acid detection rose from 
less than 6 per cent in the previous year to 33 per 
cent, and the proportion of cultures decreased by the 
same ratio. Slightly over one half of the findings were 
cultures, one third were nucleic acid detection and 
one fifth antibody testing. Of the laboratories, 18 
perform C. difficile diagnostics: 12 use nucleic acid 
detection and 6 use cultures or antigen tests as the 
primary method of analysis. The use of antibody test-
ing increased by five percentage points over previous 
years, but this change was much less significant than 
the increase in the use of nucleic acid testing and re-
duction in cultures, where the change was more than 
30%. In C. difficile diagnostics, it cannot be empha-
sised enough that the tests should should always be 
performed on diarrhoeal faecal samples that take on 
the shape of the container, the only exception being a 
situation where the patient suffers from paralytic ileus 
or a toxic megacolon. Carriers showing no symptoms 
should not be screened. The National Institute for 
Health and Welfare types strains related to suspected 
epidemics and severe individual cases. The number 
of strains sent for typification fell markedly in 2014, 
partly due to the reduction in cultures. 
EntErohaEmorrhagic 
EschErichia coli (EhEc)
A total of 64 microbiologically confirmed cas-
es caused by enterohaemorrhagic Escherichia coli 
(EHEC) were reported to the National Infectious 
Diseases Register (1.2/100,000), about one third less 
than in 2013 (98). The incidence was highest in the 
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0 to 9 age group (4.3/100,000). Haemolytic-uremic 
syndrome (HUS) was diagnosed in six cases (9%). 
In 2014, approximately one half of infections (31; 
48%) were deemed to be of domestic origin. Ten of 
these cases were connected to the EHEC O157:H7 
epidemic that began in December 2013. Those who 
fell ill were aged between 4 and 16, from different 
parts of Finland. Laboratory testing indicated that 
the bacterial strain was identical with the EHEC 
infections diagnosed in spring 2013 (for a more de-
tailed description, see the chapter Food and water-
borne epidemics). 
A bacterial culture for a total of 61 EHEC cases was 
sent to a laboratory for confirmation. Of these, 57 
were confirmed using PCR methods and the EHEC 
strain was isolated in 56 bacterial cultures for further 
examination. Strains of serotype O157:H7 caused a 
total of 28 cases (49%), of which 19 were of domes-
tic and 9 of foreign origin. The O157 strains were 
divided into 5 phage types, most generally PT 8 (14 
strains) and PT 88 (9 strains). All PT 88 strains were 
connected to the domestic cluster first diagnosed in 
December 2013. These were positive with regard to 
the stx2 gene, were sorbitol fermenting, were immo-
bile despite the gene coding for a H7 flagella antigen, 
and six of the strains were identical by PFGE geno-
type (1.203). Of the FT 8 strains, 9 were of domestic 
origin and 5 connected to travel in Turkey. All FT 8 
strains were positive with regard to the stx1 and stx2 
genes and were sorbitol negative. They were divid-
ed into 10 different PFGE genotypes and only 1–2 
shared the same genotype. There were 28 cases of se-
rogroup Non-O157. The strains isolated from them 
were divided into 10 different non-O157 serotypes, 
the most common being O26 (5 strains), O103 (4 
strains) and O55 (4 strains). The O103 strains were 
all domestic and the O55 strains foreign, whereas the 
O26 serotype was found in both domestic and for-
eign ones. Almost all of the O26 and O103 strains 
were individual PFGE genotypes. The O55 strains 
originated in three different countries and divid-
ed into two, almost identical PFGE genotypes. Six 
strains remained untyped (ONT). 
campylobactEr
Campylobacter is the most common bacterial cause 
of gastrointestinal infections in Finland. In 2014, 
4,887 findings of campylobacter were reported, over 
800 cases more than in 2013 (4,067). Campylobacter 
jejuni remained the single most common type of 
campylobacter (4,143 cases); there were 326 reported 
cases of C. coli, and 393 cases in which the type of the 
campylobacter finding was unspecified. 
The incidence in the entire population was 
90.1/100,000. Men accounted for 54.4 per cent of 
the cases. The highest number of cases was report-
ed in the age group 20 to 54 (136.1/100,000). Inci-
dence was highest in the hospital district of Helsinki 
and Uusimaa (133.1/100,000).
The seasonal variation was typical of campylobacter: 
the incidence was highest in July–August. Of the 
cases in 2014, 828 (16.9%) were domestic in origin, 
although in 32.8% of the cases data was lacking on 
the country of acquisition. Foreign travel was a fac-
tor in 50.3% (2,457) of the cases; the most common 
source being Spain (291), followed by Turkey (262) 
and Thailand (245).
The reason for the considerable increase in the num-
ber of campylobacter infections remains unknown. 
There were no major outbreaks of domestic epidem-
ics in 2014. Since a large number of notifications still 
lack data on the country of acquisition, it is difficult 
to assess the number of infections of domestic ori-
gin. More information on the country of origin and 
sources of campylobacter infections would be neces-
sary if prevention measures are to be targeted. 
The bacterial cultures of 17 cases of campylobacter 
were analysed in a laboratory; 14 of these were con-
nected to two clusters. The PFGE genotype of each 
of six strains found in July in the Mikkeli and Savon-
linna regions in eastern Finland was different.  In re-
lation to the waterborne outbreak in Sipoo, southern 
Finland, in October, four identical PFGE genotypes 
were diagnosed.
listEria
In 2014, a total of 65 severe systemic infections 
caused by the bacterium Listeria monocytogenes were 
diagnosed (2013: 61). Of these cases, one half were 
over the age of 75 and 60 per cent were men. The 
listeria cases were spread out across the country. As 
yet, information on pregnancy is not reported to the 
National Infectious Diseases Register, but one case 
of listeriosis was diagnosed in a newborn baby on 
the basis of laboratory referrals. Upon the introduc-
tion of electronic notification of infectious diseases 
by physicians, surveillance data for listeriosis will be 
specified.
The Listeria monocytogenes strain of a total of 65 
patients arrived for typing at a laboratory; 63 strains 
were isolated from the patient’s blood and/or cere-
Report 14/2015 
National Institute for Health and Welfare
Infectious Diseases in Finland 2014
19
brospinal fluid, one from the genital mucous mem-
brane and one from a paracentesis sample. The PCR 
method was used for determining the Listeria mono-
cytogenes serotype. Of the strains, 45 (69%) were of 
serotype IIa (corresponding to serotype 1/2a and 3a 
when using the earlier method) and 16 (25%) were of 
serotype IVb (serotypes 4b, 4d and 4e). These strains 
were divided into 44 PFGE genotypes. The majority 
of infections (51/65, 78%) were isolated (the same 
strain in two persons at most). The typifications re-
vealed three clusters of four to six persons. In June–
August, the strain Asc70-Apa5 was diagnosed in four 
persons, in September–November the strain Asc14-
Apa5 in five persons, and in January–October, the 
strain Asc96-Apa1 in six persons. 
Up-to-date DNA typing data on L. monocytogenes 
strains was sent to the international database coordi-
nated by the ECDC. In 2014, five international clus-
ters were found that included the DNA profiles of 
Finnish strains. Of the clusters diagnosed in Finland, 
two (Asc70-Apa58, Asc96-Apa1) were also present in 
other parts of Europe.
salmonElla
In 2014, a total of 1,622 salmonella cases were re-
ported (2013: 1,987), of which 54 per cent were 
detected in women. The annual incidence in the 
entire country was 29.9/100,000 population. The 
incidence was highest in the North Savo Hospi-
tal District (43.1/100,000) and lowest in the Åland 
(14.0/100,000), The highest number of infections 
was reported in the 50 to 54 age group.
Five cases of the S. Typhi bacterium, which causes ty-
phoid fever, were identified. Three of the patients had 
travelled in India and two in Tanzania. Five cases of 
S. Paratyphi (Paratyphi A), which causes paratyphoid 
fever, were found. 
The bacterial strain of a total of 1,428 cases of sal-
monella was sent to the National Institute for Health 
and Welfare, almost a fifth fewer than in the previ-
ous year (1,777). Of these, 1,113 (78%) were infec-
tions of foreign and 295 (21%) of domestic origin. 
The incidence of Salmonella infections contracted in 
Finland was 5.4/100,000 (in 2013: 6.2/100,000). In 
20 (1%) cases, the origin of the salmonella infection 
remained unclear. All strains were serotyped. Anti-
microbial susceptibility testing and further typing 
according to serotype was performed on all strains 
of domestic origin, and selectively on approximate-
ly one half of foreign strains. Selection focussed on 
strains originating in the WHO/European countries 
(53 countries in Europe and close by), but was ran-
dom with regard to serotype.
Domestic salmonella infections were caused by 50 
different serotypes. The three most common, in-
cluding Typhimurium (92 cases), Enteritidis (49) 
and group B (32), caused 59% of infections. Most 
(206/295, 70%) cases were still susceptible to all 12 
antimicrobials tested, and the proportion of multi-
resistant strains remained on a par with the previous 
year (2014: 59/295, 20% vs. 2013: 70/337, 21%) 
and 10% of the strains were resistant to ciprofloxacin 
(CIP MIC >0.06) (30/295). Five strains were resis-
tant to cefotaxime (Kentucky, group B, Typhimuri-
um, Thompson, Stanley). No strains with lower sus-
ceptibility to imipenem were found. Of the domestic 
strains of Typhimurium, 17% (16/92) were multire-
sistant. The percentage of the traditional endemic PT 
1 phage type (32%) was higher than in the two previ-
ous years, but lower than a few years ago (2013: 27%, 
2012: 23% and 2011: 60%). As in previous years, 
the majority of PT 1 strains (90%) were susceptible 
to antimicrobials and divided into ten MLVA geno-
types, of which the most common was 3-16-NA-NA-
0311. Unspecified phage types that caused a reaction 
(PT NST) were found in 38% of cases. The usual 
number (49) of cases were caused by the domestic 
Enteritidis serotype, and no clusters caused by any 
individual strain were found. Most strains were sus-
ceptible to all antimicrobials tested (33/49, 67%), 
but 30% (15/49) were resistant to ciprofloxacin. En-
teritidis strains were divided into 17 different phage 
types, the most common being PT 8 (24%). NT and 
NST strains accounted for 10% of cases. A total of 
21 different PFGE genotypes were found in all, the 
most common being SENT 115 (12), which was di-
vided between five phage types and nine MLVA types. 
The number of domestic group B cases (32) has sta-
bilised at the level of the three previous years since 
the increase of a few years ago. Most of the strains in 
group B were so-called monophasic S. Typhimurium 
strains. All monophasic Typhimurium strains isolated 
from infections of domestic origin were multiresis-
tant; most commonly to ampicillin, streptomycin, 
sulfonamide and tetracycline. This resistance gives 
us reason to suspect that the monophasic Typhimu-
rium strains are actually of foreign origin (e.g. sec-
ondary cases related to someone who returned from 
abroad or originating in an imported food product). 
Multiresistant monophasic Typhimurium strains are 
not known to occur in domestic farm animals. The 
most common monophasic phage type has varied in 
previous years (PT 195, PT 193, NT/NST), but in 
2014, PT 120 was most common. The multiresistant 
monophasic Typhimurium strain PT 120, MLVA 
3-12-17-NA-0211 caused an epidemic in Finland 
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Figure 7. Salmonella and campylobacter cases by month, 2003–2014 (no. of cases).
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Table 1. The most common serotypes of salmonella cases, 2007–2014 (excluding S. Typhi and S. Paratyphi) 
(no. of cases).
2007 2008 2009 2010 2011 2012 2013 2014
Infection acquired abroad (source: nIdr)
Salmonella Enteritidis 732 1065 654 777 640 545 519 446
Salmonella group B 92 168 121 102 145 160 170 116
Salmonella Typhimurium 196 177 148 122 84 83 79 73
Salmonella Stanley 174 136 111 98 70 99 69 44
Salmonella Corvallis 58 70 68 42 46 42 35 41
Salmonella Newport 57 76 54 53 32 31 27 39
Salmonella Infantis 54 31 42 42 31 44 36 30
Salmonella Weltevreden 25 14 36 14 27 18 20 28
Salmonella Hadar 22 24 17 27 11 17 12 24
Salmonella Braenderup 52 36 39 37 22 37 13 23
domestically acquired infections (source: bacterial Infections unit)
Salmonella Typhimurium 156 85 140 132 94 98 94 92
Salmonella Enteritidis 62 48 51 44 47 83 46 49
Salmonella group B 11 5 7 8 40 35 38 32
Salmonella Newport 28 71 9 8 6 7 11 9
Salmonella Infantis 3 7 2 9 10 36 12 9
Salmonella Agona 40 15 2 2 11 33 12 8
Salmonella Mikawasima 5 23 1 7 3 2 3 8
Salmonella Stanley 11 8 6 7 1 3 1 6
Salmonella Thompson 0 3 2 12 2 5 9 6
Salmonella Virchow 5 6 6 4 3 1 4 5
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and occurred at the same time in five other European 
countries. The source remained undetected, but meat 
was suspected. 
Salmonella infections acquired abroad represented 99 
serotypes. The most common serotypes were the same 
as in the two previous years: Enteritidis (391/1,113, 
35%), Group B (105), Typhimurium (67) and Stan-
ley (44). The leading countries of acquisition for 
cases of foreign origin were Thailand (30%), Tur-
key (14%), Spain (6%), Indonesia (4%) and Russia 
(3%). The number of strains originating in WHO/
European countries decreased by almost one quar-
ter from the previous year (402 vs. 532). Enteritidis 
(256/402, 64%) was still the most common serotype. 
The percentage of group B strains was only 3%. The 
number of strains originating outside the WHO/
European countries was approximately 15% lower 
than in the previous year (2014: 691 vs. 2013: 811). 
The most common serotypes were Enteritidis (128) 
and group B (90). More than one half (644/1,113) 
of the foreign strains were selected for antimicrobial 
susceptibility testing and further typing according 
to serotype. The proportion of multiresistant strains 
remained at the previous year’s level in the WHO/
European area (2014: 10% vs. 2013: 11%) and de-
creased slightly outside (2014: 24% vs. 2013: 28%). 
Enteritidis strains originating in the WHO/European 
countries that were selected for further typing were 
divided into 18 phage types; 51% were of the phage 
type PT 14b or PT 8, whereas the Enteritidis strains 
of far-off countries (N=128) were more evenly divid-
ed into 12 phage types. The group B strains (N=32) 
chosen for further typing and originating in far-off 
countries were mainly multiresistant monophasic S. 
Typhimurium strains (N=24). The most common 
phage type was PT 193 (N= 17).
shigElla
In 2014, the incidence of shigellosis was 1.6/100,000. 
Of the total of 89 cases reported, 46 were in women. 
The median age in these cases was 36 years (range 
0–74). The majority of cases (70) were detected in 
individuals aged 20–59. More than half of the cas-
es (64) were reported in the Helsinki and Uusimaa 
Hospital District. Ten hospital districts had no diag-
nosed cases. The lack of findings in so many hospital 
districts may well be indicative of problems in the 
primary diagnostics of shigella, which is known to 
require a high level of meticulousness when reading 
samples. The shigella strain of 86 persons was sent to 
the National Institute for Health and Welfare labora-
tory. Of the total, 73 infections (85%) were reported 
as having been acquired abroad, 13 in Finland and, 
in three cases, the country of acquisition remained 
unspecified. The most common countries of origin 
were India (13 cases) and the Dominican Republic 
(5). The prevailing shigella species were Shigella son-
nei (57 cases) and S. flexneri (19 cases). S. flexneri was 
divided into seven serotypes.
Antimicrobial susceptibility testing was performed 
on domestic strains only. One strain was susceptible 
to all 12 antimicrobials tested and the remaining 12 
were multiresistant (R to at least four of the 12 an-
timicrobials tested). One domestic S. flexneri strain 
of serotype 2a was resistant to ciprofloxacin (MIC 8) 
and cefotaxime. 
yErsinia
Under the Communicable Diseases Decree, yersin-
ia is among the bacteria that must be registered and 
reported to the National Infectious Diseases Reg-
ister, but does not need to be sent for strain collec-
tion to the National Institute for Health and Welfare. 
However, species typing and biotyping/serotyping of 
yersinia strains may pose a problem for clinical micro-
biology laboratories. Since the beginning of 2014, even 
problematic strains have not been routinely accepted. 
yersinia enterocolitica
In 2014, 499 cases of Yersinia enterocolitica were re-
ported to the National Infectious Diseases Register 
(2013: 497). The incidence rate in the entire country 
was 9.2/100,000 and highest in the 35–39 age group 
(17.0/100,000). There was great regional variation 
in the Y. enterocolitica findings, the highest incidence 
rate was in the Helsinki and Uusimaa Hospital Dis-
trict (17.1/100,000), Kymenlaakso (13.2/100,000) 
and Lapland (11.8/100,000), and only one case was 
diagnosed in each of five hospital districts in 2014.
Y. enterocolitica is most commonly confirmed from 
a stool culture. In 2014, stool cultures were used to 
confirm 450 cases, while only 44 cases were confirmed 
by antibody findings in serum; in five cases, both an-
tibody typing and a stool culture were used. In the 
Helsinki and Uusimaa hospital district, the typing re-
sult for Y. enterocolitica was given in 77% (185/238) 
of the cases confirmed by culture. Of these, 55% were 
of the biotype 1A. BT 1A is a heterogenous group of 
strains that lack the pYV virulence plasmid typical of 
pathogenic yersinias. However, some BT 1A strains 
may have other properties affecting their pathogenic 
capabilities. Other hospital districts reported only in-
dividual cases of typing, which means that no conclu-
sions on the percentage of various biotypes/serotypes 
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Figure 9. Rotavirus cases by age group in children aged 0 to 4, 2005–2014 (no. of cases).
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Figure 8. Cases of norovirus infection per month, 2005–2014 (no. of cases).
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or the clinical significance of findings can be drawn 
at national level.
yersinia pseudotuberculosis
The number of Yersinia pseudotuberculosis cases (74) 
was clearly higher than in the previous year (39). The 
incidence for the entire country was 1.4/100,000 in-
habitants. Of the cases, 53 were typed by culture and 
only 20 by antibody findings; both were used in one 
case. The majority of infections were diagnosed in 
April (44). The increase in cases in the spring was due 
to the Yersinia pseudotuberculosis outbreak connected 
to unprocessed milk in the region of Porvoo (for a 
more detailed description, see Food and waterborne 
epidemics). 
The National Institute for Health and Welfare analy-
sed the Y. pseudotuberculosis strain in relation to 42 
persons. One was a strain isolated from blood and the 
others were analysed when investigating an epidemic 
caused by unprocessed milk. All strains related to the 
epidemic were of serotype O:1. Moreover, the strain 
related to eight persons was analysed using PFGE 
typing, and that of seven using MLVA typing. The 
results showed that the patients’ strains were identical 
Report 14/2015 
National Institute for Health and Welfare
Infectious Diseases in Finland 2014
23
with each other and the Y. pseudotuberculosis strains 
isolated from the unprocessed milk and the milk con-
tainer filter on the farm. Y. pseudotuberculosis strains 
of different genotype were also isolated on the farm.
norovirus
In 2014, 1,361 cases of norovirus were reported to 
the National Infectious Diseases Register. Notifica-
tions were submitted by all hospital districts. Cases 
occurred in all age groups, but one half of them were 
diagnosed in persons over 75 years old. The percent-
age of women was 57%.
Norovirus is one of the most common causes of water 
and food-borne epidemics. As in previous years, most 
cases of norovirus occurred in January‒May (842, 
60%). In July–August, 15 suspected bathing wa-
ter borne epidemics from different parts of Finland 
were reported to the national register IT system for 
food- and water-borne epidemics. In three epidemics, 
norovirus was confirmed as the cause, isolated from 
both patient samples and samples taken from bathing 
water or beach environments. Norovirus of the geno-
type GI.2 was diagnosed in the samples of patients 
who had bathed in Lake Lämsänjärvi in Oulu and 
contracted gastroenteritis. Likewise, the dominant 
norovirus type of patients who had bathed in Lake 
Tohloppijärvi in Tampere was GI.2. In addition, no-
rovirus types GI.4 and GII.2, and highly transformed 
noroviruses of type GI.7 were detected in Tampere. 
GII.4 and GI.2 were diagnosed in the samples of pa-
tients who had bathed in Lake Pohjoinen Myllyjärvi 
in Espoo. (For a more detailed description, see Food 
and waterborne epidemics).
In 2014, noroviruses GII.P2, GII.4 and GIIP.7 of the 
genogroup II, and recombinant virus GII.3/GII.P21 
caused most food-borne epidemics. Of the viruses in 
genogroup I, GI.2 and GI.P6 were diagnosed. 
rotavirus
In 2014, 274 cases of rotavirus were reported to the 
National Infectious Diseases Register. The number 
of cases has remained below 500 since the rotavirus 
vaccine was introduced to the national vaccination 
programme in September 2009. Comprehensive ro-
tavirus vaccinations for young children have clearly 
lowered the incidence of rotavirus infections in under 
5-year-olds (2014: 38/100,000) in comparison with 
the average incidence (460/100,000) in this age group 
prior to the vaccination programme. A continuously 
increasing percentage of cases occur in patients aged 
5 and older (2014: 63%), whereas the percentage of 
such cases before the vaccinations was approximately 
10%. More than one half of rotavirus cases in chil-
dren under 5 years of age occurred in unvaccinated 
individuals. 
The National Institute for Health and Welfare main-
tains the microbial strain collection of rotaviruses in 
accordance with the Communicable Diseases Act and 
Decree and is monitoring whether the virus strains 
reduced by vaccination are being replaced by other vi-
rus strains. Rotavirus positive findings sent by clinical 
laboratories to the National Institute for Health and 
Welfare are typed on the basis of molecular genetics 
by the University of Tampere Vaccine Research Cen-
ter. As in 2013, the most common type of rotavirus 
that caused outbreaks of cases was genotype G2P[4]. 
Other frequently found genotypes included G1P[8], 
G3P[8], G4P[8], G9P[8] and G12P[8]. Genotypes 
G8P[14], G6P[14] and G8P[8] also caused a few 
cases. The clinical presentations caused by different 
types of rotaviruses are highly similar.
vibrio cholEraE
Pursuant to the Communicable Diseases Decree, 
strains of Vibrio cholerae are sent to the National In-
stitute for Health and Welfare’s expert laboratory for 
further analysis. In 2014, 45 strains were analysed. 
This number was exceptionally high in comparison 
with previous years (1‒17). The infected patients 
were aged between 3 and 93, 17 were under 10 and 
8 were over 75 years of age. Almost two thirds of the 
infected patients were men. The samples were taken 
in July‒December, mainly in August (28/45). Eight 
strains were isolated from blood, 11 from ear secre-
tions. One of the strains was of serotype O1, Inaba 
and biotype El Tor, but it lacked the cholera toxin 
coding ctx-gene. Others belonged to groups other 
than O1 or O139. 
Bacteria that cause the gastroenteritis cholera be-
long to serogroups O1 and O139, and produce tox-
ins. They have not been found in Finland during the 
last century, except in 1998 when the source of in-
fection was mussels smuggled to Finland from Thai-
land. More vibriobacteria are present in seawater and 
brackish water during warm summers. The majority 
of these cause skin infections.
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Hepatitis
The number of hepatitis A cases was one quarter lower year-on-year. The number • 
of hepatitis A infections of domestic origin was relatively high for the second year 
running, due to an international epidemic that spread via frozen berries. 
As in recent years, very few acute hepatitis B infections were reported. Cases of • 
chronic infection were mainly diagnosed in foreigners.
The majority of hepatitis C infections were diagnosed in Finns, having been • 
contracted through the use of intravenous drugs. 
hEpatitis a
In 2014, 27 cases of hepatitis A were reported 
(0.5/100,000), around one quarter fewer than in the 
previous year (2013: 41). The median age in these 
cases was 40 years (variation 4–82). Men account-
ed for 59% (16) of the cases, the highest number of 
them being reported in the Helsinki and Uusimaa 
Hospital District (9) and in the Pirkanmaa hospital 
district (6). Of these infections, 14 were contracted in 
Finland and 13 abroad. The percentage of domestic 
infections was relatively high for the second consecu-
tive year. The extensive international food-borne epi-
demics of recent years explain the situation. The high 
percentage of domestic infections in 2014 was due 
to the epidemic that spread via frozen berries. Cases 
were diagnosed in 13 EU/EEA countries, including 
Finland (for a more detailed description, please see 
Food and waterborne epidemics).
hEpatitis b
In 2014, 20 (0.4/100,000) acute hepatitis B infec-
tions were reported to the National Infectious Dis-
eases Register. Findings tested positive for IgM anti-
bodies are classified as acute. The number of cases was 
divided equally between men and women. Seven of 
the infected patients were of Finnish origin, 13 for-
eign. The mode of transmission was reported in six 
cases only, being sexual contact in four of these. The 
country of acquisition was, however, reported in 11 
cases. In all of them, the infection had been acquired 
abroad.
In the last ten years, the reported annual average 
number of acute hepatitis B infections is 20 whereas 
in the record year, 1998, almost 180 infections were 
reported. This decrease is mainly due to higher vacci-
nation coverage. Vaccination of risk groups began in 
the 1990s. In addition, the vaccine has been popular, 
particularly among travellers. Moreover, needle and 
syringe exchange has probably prevented infections 
among users of intravenous drugs. 
The number of chronic hepatitis B infections report-
ed was 259 (4.8/100,000), 56% in men and 44% in 
women. The majority, 86% of infections, were di-
agnosed in persons of foreign origin. The mode of 
transmission was reported in only 15% of cases, with 
perinatal infections and infections due to sexual con-
tact being most common. 
The number of cases of chronic hepatitis B has de-
creased since it peaked at over 600 in 1996. The 
decline has been sharp for infections in people of 
Finnish origin, whereas the number of infections in 
foreigners has not changed significantly during the 
monitoring period. 
hEpatitis c
In 2014, 1,225 new cases of hepatitis C (23/100,000) 
were reported to the National Infectious Diseases 
Register, the incidence being highest (89/100,000) 
in the 20 to 24 age group. Men accounted for 66% 
of the cases, and intravenous drug use was the most 
common transmission mode (55%). Information on 
the mode of transmission was lacking in 34% of the 
cases. Sexual contact was given as the mode of trans-
mission in seven per cent of cases, most being het-
erosexual contact (55), but six were acquired through 
sexual contact between men. 
The majority of patients (84%) were Finnish. Of the 
foreigners infected, more than half were born in the 
Soviet Union, Russia or Estonia. The country of ac-
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Figure 10. Hepatitis C by age group, 2003–2014 (no. of cases).
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Table 2. All cases of hepatitis C according to physicians’ reports, by transmission routes, 2003–2014 (no. of 
cases).
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Injecting drugs 640 619 638 582 480 582 520 635 615 653 648 684
Sex 48 63 65 80 71 82 75 80 88 67 88 85
Perinatal 1 11 5 5 3 11 10 10 12 7 4 4
Blood products 21 18 24 8 24 20 5 13 8 7 11 13
Other 38 34 39 45 37 41 47 50 39 31 41 35
Unknown 531 515 498 478 577 431 415 376 399 406 383 410
total 1279 1260 1269 1198 1192 1167 1072 1164 1161 1171 1175 1231
quisition was known in 62% of the cases. In most of 
them (88%), the country of infection was Finland. 
The highest incidence of infections in relation to 
population were reported in the hospital districts of 
East Savo (49/100,000), Länsi-Pohja (37/100,000) 
and South Savo (32/100,000) and the lowest in Cen-
tral Ostrobothnia (12/100,000), South Ostrobothnia 
(16/100,000) and Satakunta (16/100,000).
The majority of hepatitis C infections were reported 
without an identity number in 1995‒1997. The high 
figures for hepatitis C in 1996–2000 (1,800 cases on 
average per year) may have been partially due to cas-
es without identity numbers being registered several 
times, and the probable registration for those years 
of many cases initially diagnosed before monitoring 
began. Since 2003, the annual number of cases has 
varied between 1,100 and 1,200, the lowest figure be-
ing recorded in 2009 (1,036). No significant changes 
in the distribution of age groups have occurred in the 
last five years.
The majority of infected patients in Finland were in-
travenous drug users. A very high percentage, around 
80%, of intravenous drug users have been found to 
have hepatitis C antibodies. Because of this, it is dif-
ficult to reduce the number of infections further in 
this group by means of needle and syringe exchange 
programmes alone.
In 2014, hepatitis C genotypes completed by the end 
of the year 2013 (6,200 patients) were recorded in 
the National Infectious Diseases Register. Genotyp-
ing is principally conducted only for patients referred 
to treatment. The most common genotypes were 
GT3 (49%), GT1 (25%) and GT2 (11%). 
At year end 2014, the National Institute for Health 
and Welfare published an extensive report on the oc-
currence and consequences of hepatitis C virus infec-
tions in Finland in 1995‒2013.
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Figure 11. Incidence of hepatitis C in Finland in 2014, no. of cases per population of 100,000.
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Sexually transmitted diseases
The majority of chlamydia cases were detected in individuals aged 15–29.• 
The number of gonorrhoea infections diagnosed was around 20 more than in the • 
previous year. More than half of the infections were acquired in Finland.
More than one in three gonorrhoea infections were contracted through sexual • 
contact between men.
The number of syphilis infections was 50 more than in the previous year, most • 
originating in Russia and Estonia.
Approximately twenty more HIV infections were diagnosed than in the previous • 
year. Most HIV infections of Finns acquired through heterosexual contact were of 
foreign origin, in Thailand in particular.
Almost one half of syphilis, gonorrhoea and HIV infections contracted by Finnish • 
men were the result of sexual contact between men.
Figure 12. Chlamydia cases in the young adult age groups, 2003–2014 (no. of cases).
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chlamydia (chlamydia 
trachomatis)
chlamydia
In 2014, a total of 13,220 cases of chlamydia 
(244/100,000) were reported, a figure almost equal 
to that of the two previous years. The highest num-
ber of infections, accounting for 35% of all cases, 
was reported in the Helsinki and Uusimaa Hospi-
tal District, where the incidence was also highest at 
297/100,000.
Of these infections, 58% were reported in women, 
42% in men and the majority, 82%, were detected 
in the age group 15 to 29. The incidence was highest 
(1,635/100,000) in the age group 20 to 24. The ma-
jority (94%) of these patients were Finnish. 
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2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Finland 89 133 133 112 79 90 115 123 106 164 154 143
Thailand 27 38 30 42 44 34 36 45 35 35 31 23
Estonia 2 6 1 0 2 0 0 3 8 6 0 8
Russia 9 7 23 12 6 17 8 8 6 7 3 2
Other 21 21 20 25 22 24 40 33 41 55 49 63
Unknown 41 47 33 45 42 35 40 45 92 45 31 47
total 189 252 240 236 195 200 239 257 288 312 268 286
Table 3. Gonorrhoea infections acquired domestically and abroad, 2003–2014 (no. of cases).
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Finland 30 22 25 21 56 57 69 36 29 55 25 45
Russia 18 16 22 18 17 26 18 26 22 27 22 22
Estonia 6 1 6 3 4 9 3 9 4 6 4 11
Thailand 1 2 1 1 2 6 5 4 5 6 5 8
Other 16 12 21 20 29 43 40 50 45 41 28 48
Unknown 62 58 68 67 79 75 67 84 74 66 72 69
total 133 111 143 130 187 216 202 209 179 201 156 203
Table 4. Syphilis infections acquired domestically and abroad, 2003–2014 (no. of cases).
lgv
Cases of LGV (lymphogranuloma venereum), caused 
by Chlamydia trachomatis, have been reported to the 
National Infectious Diseases Register since 2011. Of 
the total of 17 infections, two were reported in 2014. 
All infections were diagnosed in men, and all but one 
in Finns. The mode of transmission is known for 16 
cases, and in 15 of them it is sexual contact between 
men. In one case, sexual contact with both genders 
was reported.
gonorrhoEa (nEissEria 
gonorrhoEaE)
In 2014, 286 gonorrhoea infections (5.3/100,000) 
were diagnosed, twenty more than in the previous 
year. The highest number of infections, accounting 
for 65% of all cases, was reported in the Helsinki and 
Uusimaa Hospital District, where the incidence was 
highest as well at 11.9/100,000.
Of these infections, 73% were reported in men and 
27% in women and the majority of infections, 63%, 
occurred in the age group 20 to 35. The incidence 
was highest (20.9/100,000) in the age group 20 to 
24. The majority (82%) of infections were diagnosed 
in Finns.
The mode of transmission was known in 90% of the 
cases. 39 per cent of the infections in men were con-
tracted through sexual contact between men. The 
country of acquisition was reported in 83% of the 
cases, being Finland in 64%. As in previous years, the 
majority of infections contracted abroad originated 
in Thailand.
The infections are predominantly analysed using a 
nucleic acid test. In 2013, only around one half of 
the cases were subjected to antimicrobial susceptibil-
ity testing. By the end of the year 2013, no Gonococ-
cus strain resistant to ceftriaxon had been reported in 
Finland.
syphilis (trEponEma 
pallidum)
In 2014, 203 gonorrhoea infections (3.7/100,000) 
were diagnosed, over 50 more than in the previous 
year. The number of cases reported annually includes 
both active cases of syphilis and old serological scars. 
Of the cases, 58% were reported in the Hospital Dis-
trict of Helsinki and Uusimaa. The incidence was 
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Figure 13. HIV cases by transmission route, 2003–2014 (no. of cases).
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highest (8.3/100,000) in the Hospital District of 
South Karelia.
Of the infections, 64% were reported in men, 36% 
in women The majority of infections, 57%, were di-
agnosed in the age group 30 to 49. The incidence was 
highest (11.5/100,000) in the age group 35 to 39. 
Foreigners accounted for 51% of all cases.
The mode of transmission was known in 55% of the 
cases. More than half (56%) of the sexually transmit-
ted infections in men were contracted through sexual 
contact between men.
The country of acquisition was reported in 66% of the 
cases, of which 71% were contracted abroad. How-
ever, around two out of three of infections in Finns 
were contracted in Finland. As in previous years, the 
majority of infections contracted abroad originated 
in Russia and Estonia. 
hiv and aids
In 2014, 181 new HIV infections were diagnosed (in-
cidence 3.3/100,000). The highest number of infec-
tions, accounting for 57% of all cases, was reported 
in the Helsinki and Uusimaa Hospital District, where 
the incidence was also highest, at 6.6/100,000. Sev-
enteen cases of AIDS, and two deaths due to AIDS, 
were reported.
Of the infections, 77% were diagnosed in men, 23% 
in women. Foreigners accounted for 51% of all cases. 
The majority of infections in Finns (90%) were re-
ported in men, but the percentage of women, 36%, 
was higher among foreigners. 
The majority of infections (69%) were acquired 
through sexual contact. Infections acquired through 
heterosexual contact accounted for 38% and sexual 
contact between men for 31% of the cases. More 
than half of infections in Finnish men contracted 
through sexual contact were connected to sexual con-
tact between men. 
The reported number of infections contracted through 
heterosexual contact was 68. Foreigners accounted 
for 47% of all cases, and the majority of infections 
contracted through heterosexual contact originat-
ed abroad, both among foreigners and Finns. As in 
previous years, Thailand was a prominent source of 
infection for Finns who had acquired the infection 
abroad.
The number of infections due to sexual encounters 
between men was 56. Foreigners accounted for 25% 
of all cases, The majority of infections originated in 
Finland. In recent years, Thailand has become more 
common as a foreign source of infections contracted 
by Finns, and it was the most common country of 
acquisition in 2014.
Seven cases were diagnosed in which the infection was 
acquired through intravenous drug use, six of these 
patients being foreign. Since the epidemic of the turn 
of the millennium, efficient prevention methods have 
helped to keep the number infections at a low level.
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Two mother-child infections were reported, both of 
foreign origin. A total of 39 infections were detected 
in maternity clinic screenings, eight of them new in-
fections, accounting for almost 20% of all new cas-
es in women. In the other cases, the infection was 
known about before pregnancy. In cases where it is 
known that the mother has been infected, mother-
child transmission can be effectively prevented with 
HIV medication.
Three infections caused by blood products were re-
ported, all in foreigners and all contracted abroad. 
Since HIV testing of donated blood began in Finland 
in 1985, no cases have been reported of infection 
through blood products in Finland.
Information on the mode of transmission was lacking 
in 24% of cases, the notification of infectious diseases 
by the physician not being available in 40%. Foreign-
ers accounted for over 80% of cases in which infor-
mation on the mode of transmission was lacking.
In 2014, 17 new cases of AIDS were reported, 11 
in Finns and six in foreigners. The number of HIV-
positive patients who died during the year was 17, the 
cause of death being AIDS in two cases. 
The percentage of late detection of infections (CD4 
lower than 350) was 40%. Testing should therefore 
be further enhanced and the benefits of early diagno-
sis highlighted. Preliminary analyses indicate that, in 
7% of new cases, primary resistance mutations (HIV 
drug resistance mutations transferred with the infec-
tion) were detected.
By the end of 2014, the total number of HIV in-
fections reported in Finland was 3,396. The reported 
number of HIV positive patients who died was 602, 
the cause of death being something other than AIDS 
in most cases.
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Antimicrobial resistance
The number of MRSA infections was slightly higher than in the previous year, • 
which was also revealed in blood culture findings.
The number of VRE cases was lower year-on-year.• 
The growth in the number of ESBL • E. coli findings came to a halt. The same 
applied to blood culture findings. 
The number of CPE bacteria increased slightly, but no CPE outbreaks were • 
detected.
mrsa
In 2014, 1,340 cases of MRSA (methicillin-resistant 
Staphylococcus aureus) were reported, slightly more 
than in the year before (2013: 1,285). The number of 
MRSA cases confirmed through blood culture find-
ings was also higher than in the previous year (2014: 
46; 2013: 30). Of the MRSA blood culture findings, 
15 were in the Helsinki and Uusimaa Hospital Dis-
trict (1.0/100,000), eight in the Pirkanmaa Hospital 
District (1.6/100,000) and seven in the North Ostro-
bothnia Hospital District (1.7/100,000). The num-
ber of cases in other hospital districts varied from zero 
to four, totalling 16. Most (30 out of 45) of the in-
vasive cases occurred in patients older than 65, and 
two in children. The total number of cases was high-
est in the hospital districts of Helsinki and Uusimaa 
and Pirkanmaa, as were incidence figures. As before, 
almost 40 per cent of the findings were related to pa-
tients aged 75 or over. The number of MRSA cases in 
children did not increase (2014:108; 2013: 113).
The MRSA strain was typed in 1,389 individuals. 
There were 205 different spa types among the MRSA 
strains (2013: 211). The three most common spa types 
were the same as in previous years: t172 19% (2013: 
18%), t008 11% (2013: 11%) and t067 10% (2013: 
16%). The next most common spa types, t002, t032, 
t020, t019 and t044, occur evenly at 3% (for all of 
them) and t172 was found in 15 hospital districts. 
The incidence of spa type t067 clearly decreased in 
2014. As in 2013, the incidence of t067 was most fre-
quent in the hospital districts of Pirkanmaa and South 
Ostrobothnia. The marked increase in the incidence 
of the t067 strain detected in 2013 in the Hospital 
District of South Ostrobothnia halted and took a 
downward turn in 2014 (2013: 63, 2014: 32).
In addition, local clusters were caused, among oth-
ers, by t9408 in the North Savo Hospital District, 
by t1012 and t310 in the Pirkanmaa Hospital Dis-
trict and t509 in the Helsinki and Uusimaa Hospital 
District.
The two most common spa types among patients over 
75 were t172 at 19% (2013: 18%) alongside last year’s 
most common spa type t067 at 17% (2013: 26%). 
The most common spa types among children under 
the age of 16 were t008 at 14% (2013: 6%), t172 at 
12% (2013: 18%) and t044 at 8% (2013: 13%). 
An invasive MRSA strain was typed in 39 individuals. 
The most common spa types were the same as in the 
previous year: t172 (2014: 6, 2013: 2), t008 (2014: 
6, 2013: 3) and t067 (2014: 5, 2013: 5). There were 
three cases of spa type t032, two of each of spa types 
t020, t091 and t127, and the remaining cases (13/39) 
each represented different spa types.
In 2014, six MRSA strains with the mecC gene were 
isolated from clinical samples (2013: 3). There were 
two cases of spa types t10471 and t843 and one of 
spa types t3256 and t9397, respectively. 
In recent years, spa types of the MRSA CC398 com-
plex, related to production animals, have become in-
creasingly common in Europe. These strains have so 
far been rare in Finland. In 2007–2014, 48 strains of 
the CC398 complex were typed. The most common 
spa type, t034, has caused non-invasive MRSA infec-
tions and the numbers have risen slightly (2014: 14, 
2013: 5, 2012: 2). One blood finding has been re-
corded in Finland (2013: t12593). Other spa types of 
the CC398 complex found in Finland include t011, 
t108, t899 and t2741. 
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Figures 14a and 14b. MRSA cases by hospital district, 2003–2014 (no. of cases).
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The number of reported cases of the vancomycin-
resistant enterococcus (VRE) in 2014 decreased on 
the previous year (2014: 32, 2013: 45). Most cases 
were reported by the hospital districts of Helsinki 
and Uusimaa (13) and Central Ostrobothnia (12) 
and in the over 65 age group (17/32). In other hospi-
tal districts, the number of findings varied from zero 
to two. None of the findings were based on blood 
samples. In fact, VRE has rarely been found in blood 
overall (2013: 0, 2012: 1). Findings of E. casseliflavus- 
and E. gallinarum in strains lacking the vanA or vanB 
gene were erroneously recorded as VRE findings in 
blood in the 2013 report. Because these species are 
inherently less susceptible or resistant to vancomycin, 
they do not constitute actual VRE findings. 
Of the 32 VRE findings typed in 2014, 30 were of 
the species E. faecium and two of the species E. faeca-
lis. More vanB genes than vanA genes were found in 
these species (vanB 17; vanA 14) and one E. faecium 
strain had both genes of acquired resistance to vanco-
mycin, vanA and vanB. In addition, one strain of E. 
casseliflavus with an acquired vanB gene was detected 
in 2014. The typed strains were all individual find-
ings and had specific pulsed field gel electrophoresis 
(PFGE) profiles.
Esbl
Since the beginning of 2008, findings of Escherichia 
coli and Klebsiella pneumoniae exhibiting either re-
duced susceptibility or resistance to third-generation 
cephalosporin (I for intermediate and R for resistant, 
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all  
mrsa findings
s. aureus blood culture  
findings
mrsa blood culture findings and the 
methicillin resistance of s. aureus (%)
1995 89 627 2 (0,3)
1996 110 667 0 (0,0)
1997 121 747 4 (0,5)
1998 190 719 5 (0,7)
1999 212 813 8 (1,0)
2000 266 850 4 (0,5)
2001 340 887 4 (0,5)
2002 600 989 9 (0,9)
2003 859 981 7 (0,7)
2004 1478 1057 30 (2,8)
2005 1375 1012 27 (2,7)
2006 1330 1237 37 (3,0)
2007 1255 1109 32 (2,9)
2008 1729 1164 40 (3,4)
2009 1269 1208 31 (2,6)
2010 1268 1376 26 (1,9)
2011 1327 1486 44 (3,0)
2012 1288 1485 30 (2,0)
2013 1285 1590 30 (1,9)
2014 1340 1925 46 (2,4)
Table 5. MRSA-findings and their percentage of S. aureus blood culture findings, 1995–2014 (no. of cases and %). 
Esbl 
findings
e. coli  
blood culture findings
esbl e. coli blood culture findings and 
percentage of esbl of e. coli
2008 1673 2813 43 (1,5)
2009 2177 2990 77 (2,6)
2010 2559 3229 112 (3,5)
2011 3144 3476 149 (4,3)
2012 3689 3463 203 (5,9)
2013 4463 3876 233 (6,0)
2014 4190 4364 232 (5,3)
Table 6. E. coli findings with reduced susceptibility to third-generation cephalosporins (possible ESBL, extend-
ed-spectrum β-lactamase) and ESBL percentage, 2008–2014 (no. of cases and %).
respectively) have been reported to the National In-
fectious Diseases Register. The majority of these bac-
teria are extended-spectrum beeta-lactamase- produc-
ing, so-called ESBL strains that split penicillin and 
cephalosporins.
In 2014, the majority of ESBL findings were E. coli 
(4,190; in 2013: 4,463) and a small minority of K. 
pneumoniae strains (312; in 2013: 238). E. coli ESBL 
findings were made in all age groups – 76% in wom-
en and over half in patients aged 65 years or more. 
Less than one half of findings (45%, 1,976/4,190) 
were based on urine cultures. The largest number of 
cases was found in the Hospital District of Helsin-
ki and Uusimaa (1,319, 84/100,000), but the inci-
dence was highest in the Central Ostrobothnia and 
Lapland hospital districts (113, 101/100,000, respec-
tively) and in Åland (147/100,000). The number of 
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Esbl  
findings
K. pneumonia  
blood culture findings
esbl K. pneumoniae blood culture find-
ings and percentage of esbl of  
K. pneumoniae
2008 116 414 4 (1)
2009 156 476 6 (1,3)
2010 190 506 16 (3,2)
2011 243 453 16 (3,5)
2012 242 578 17 (2,9)
2013 238 567 15 (2,6)
2014 312 631 20 (3,2)
Table 7. K. pneumoniae findings with reduced susceptibility to third generation cephalosporins (possible 
ESBL, extended-spectrum β-lactamase) and ESBL percentage, 2008–2014 (no. of cases and %).
blood culture findings was equal to the figures for 
2013 (232 vs. 233) (the ESBL proportion in E. coli 
blood cultures: 232/4,364, 5.3% vs. 6.0% in 2013). 
Of these, 24% were in the Hospital District of Hel-
sinki and Uusimaa. However, the incidence of blood 
culture findings was highest in the Hospital District 
of Vaasa.
More than 60% of ESBL findings involving K. pneu-
moniae were diagnosed in patients aged 65 or over 
but, at 66 per cent, the percentage of such women 
was smaller than those with E. coli ESBL findings. 
More than one third of diagnoses (37%, 122/331) 
were based on urine. The largest number of cases 
was recorded in the hospital districts of Helsinki and 
Uusimaa (100) and North Ostrobothnia (32), while 
the incidence was highest in the hospital district of 
Kainuu. Twenty (2013:15) of the findings were based 
on blood (the ESBL proportion in the K. pneumoniae 
blood cultures: 20/631, 3.2% vs. 2013: 2.6%).
The percentage of E. coli findings exhibiting reduced 
susceptibility to third-generation cephalosporin had 
increased from 2008 to 2013, both for all findings 
and those isolated from blood, but this trend seemed 
to come to a halt in 2014. 
cpE (carbapEnEmasE-
producing EntErobactEria)
In 2014, 18 strains of carbapenemase-producing en-
terobacteria (carbapenemase-producing Enterobacte-
riaceae, CPE) were isolated in 14 individual patients. 
The figure has risen slightly from 2009, when moni-
toring began. Most findings involved K. pneumoniae 
strains and the most common carbapenemase was 
NDM. No CPE outbreaks were detected in 2014. 
More than one strain of CPE bacteria was found in 
two patients. 
As before, the majority (70%) of CPE infections were 
probably acquired abroad, but in some cases domes-
tic infection could not be excluded. CPE infections 
had been acquired in Asia and Southern Europe in 
particular. 
In 2009–2014, KPC was the most common carbap-
enemase found in Finland, most often in a K. pneu-
moniae strain. KPC-K. pneumoniae ST 512 is the 
only strain of CPE bacteria that has caused an out-
break in Finland. NDM is the second most common 
carbapenemase, most often seen in E. coli strains.
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cpe findings
bacterial strains patients
2009 5 5
2010 8 8
2011 12 11
2012 9 8
2013 13/22* 12/20*
2014 18 14
Table 8. Carbapenemase-producing Enterobacteriaceae (CPE), 2009–2014, (no. of cases).
*Including KPC outbreak (10 strains from 9 patients).
country Gene patients
No preceding travel history
KPC* 1
NDM 2
Unknown OXA-23 1
India NDM 3
Greece**
KPC 2
VIM 1
Thailand***
NDM 1
KPC 1
Spain OXA-48 1
Vietnam NDM 1
Table 9. Carbapenemase-producing Enterobacteriaceae (CPE) and possible foreign contact 2014 (no. of cases).
* One patient, two separate specimens.
** One patient, three different CPE-strains: KPC-E. coli, KPC-K. pneumoniae and VIM-K. pneumoniae
*** One patient with KPC-E. coli and KPC-K. pneumoniae
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Tuberculosis
One third of patients contracting tuberculosis were foreigners; of these, almost • 
80% were aged between 15 and 44.
The number of multiresistant cases of tuberculosis was slightly higher than • 
before. 
Several cases of mass exposure were diagnosed across the country. In all of • 
these, the index case was a young person from a country with a high incidence of 
tuberculosis.
tubErculosis 
(mycobactErium 
tubErculosis)
Incidence of tuberculosis 2014
The number of tuberculosis cases was 260 
(4.8/100,000), 11 cases fewer (4%) than in 2013 
(271; 5.0/100,000). Of these, 196 (75%) were cases 
of pulmonary tuberculosis, 80 (41%) of which pro-
duced a positive sputum stain test. There were 213 
cases of tuberculosis confirmed by culture (82%), 9 
more than in 2013 (204). According to physicians’ 
notifications, 16 patients (6%) had a previous history 
of tuberculosis diagnosed after 1950, when anti-tu-
berculosis medication became available.
The increase in the overall number of tuberculosis 
cases in Finland in 2007 and 2008 compared to 2006 
can be explained by the introduction in 2007 of the 
broader EU definition of tuberculosis cases. The an-
nual numbers of cases confirmed by culture are com-
parable throughout the monitoring period. The num-
ber of these cases remained stable from 2007 to 2011 
except in 2009, when an exceptionally large number 
of cases in foreigners was recorded; in 2012–2014, 
however, the figure became stable again. 
The distribution of cases by age group was as follows: 
under 15, 8 (3%); 15 to 29, 39 (15%); 30 to 44, 34 
(13%); 45 to 59, 40 (15%); 60 to 74, 40 (15%); and 
over 75, 93 (36%). In half of all cases the patients 
were over 60 years of age, and most of them were 
born in Finland; their cases involved a reactivation of 
a latent infection contracted decades ago. Population 
reduction among the age groups in whose youth the 
incidence of tuberculosis in Finland was high, and 
the increasing number of young immigrants has led 
to a notable decrease in the average age of tuberculo-
sis patients between 2000 and 2014, from 64 to 56 
years. In 2014, eight children were diagnosed with 
tuberculosis. Three of them were children of Finnish 
origin, who had not received the BCG vaccine.
The patient was reported to be foreign in 86 cases 
(33%), i.e. born abroad and assumed to have other 
than Finnish citizenship unless the data indicates oth-
erwise. The distribution of these cases by age group 
was as follows: under 15, 3(3%); 15 to 29, 39 (45%); 
30 to 44, 27 (31%); 45 to 59, 13 (15%); and over 60, 
4 (5%). Among these, there were 59 cases (69%) of 
pulmonary tuberculosis and 27 cases (31%) of other 
forms of tuberculosis. Information on the patient’s 
country of birth or citizenship was missing in three 
cases (1%). During the year, several cases of mass 
exposure were diagnosed across the country. In all 
of them, the index case was a young person from a 
country with a high incidence of tuberculosis. 
In two (1%) of the tuberculosis cases reported in 
2014, the patient also had an HIV infection. In one 
of these cases, the HIV infection was reported as a 
new case in 2014, and in the other, the HIV infec-
tion had been registered before. Both patients were of 
foreign origin.
tuberculosis genotyping findings 2014
All new Mycobacterium tuberculosis strains were geno-
typed using the internationally standardised spoligo-
typing and MIRU-VNTR methods. In 2014, 35% of 
M. tuberculosis strains were connected to clusters. The 
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2009 2010 2011 2012 2013
Cases under surveillance 235 186 186 165 183
trEatmEnt outcomE
favourable 171 (73%) 149 (80%) 131 (70%) 122 (74%) 125 (68%)
Cured 86 94 74 63 72
Treatment completed 85 55 57 59 53
non-favourable 44 (19%) 22 (12%) 38 (20%) 27 (16%) 31 (17%)
Deceased 41 18 37 27 30
Treatment failure 3 4 0 0 0
Interrupted treatment 0 0 1 0 1
missing 20 (9%) 15 (8%) 17 (9%) 16 (10%) 27 (15%)
Transfer 10 2 7 7 3
Treatment continues at 12 
months 9 8 8 8 3
Unknown 1 5 2 1 21
Table 11. Results of outcome evaluation for treatment of microbiologically confirmed pulmonary tuberculo-
sis, 2007–2013 (no. of cases and %).
most common cluster in Finland is still the Jazz clus-
ter (106), which has been spreading in the Helsinki 
metropolitan area for a long time. Five new cases were 
diagnosed in this cluster in 2014. The second most 
common cluster is the Nordic cluster (131), which is 
also widespread in Denmark and Sweden. Four new 
cases in different parts of Finland were diagnosed in 
this cluster. Two new cases were connected to the tu-
berculosis epidemic in Turku in 2014. Two cases of 
laboratory contamination were diagnosed through 
genotyping.
tuberculosis strain susceptibility to 
medication in 2014
Of all cultured strains, 91% had full susceptibility 
and, in twenty cases, resistance to one or several drugs 
was diagnosed. Although the susceptibility to drugs 
of M. tuberculosis strains remains high, the number 
of multidrug-resistant (MDR) cases of tuberculosis 
was somewhat higher than before. Of the eight MDR 
cases confirmed through culture and diagnosed dur-
ing the year, one case was an extended-drug resistant 
(XDR) tuberculosis.
Two of the MDR cases confirmed through culture 
were in patients born in Finland, others were from 
Somalia, Russia and the Philippines. In addition to 
these, a six-year-old child born in Finland, who had 
not received the BCG vaccine, contracted MDR tu-
berculosis after being infected by its grandfather.
tuberculosis outcome surveillance in 2009–
2013
Table 11. shows the distribution of treatment out-
comes between 2009 and 2013. The domain consists 
of cases of pulmonary tuberculosis confirmed by cul-
ture, genetic replication or staining. Cases where the 
pathogen is an MDR strain are reported separately 
and are not included in Table 11. An outcome evalu-
ation is performed 12 months after the case is regis-
tered. 
The treatment outcome was good in 68% of cases in 
2013. This falls clearly short of the international tar-
get set by the WHO at 85%, but is on a par with the 
average for most EU Member States. Mortality (be-
fore beginning treatment or during treatment) was 
16% in 2013.
other mycobacteria
A total of 631 non-tuberculotic, environmental my-
cobacteria were identified (incidence 11.6/100,000). 
The most common of these found in patient samples 
were Mycobacterium avium (n=161), Mycobacterium 
gordonae (n=155) and Mycobacterium intracellulare 
(n=92), six of which were diagnosed in children un-
der the age of 5.
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Other infections
Severe pneumococcal diseases caused by vaccine serotypes have almost vanished • 
in young children and continued to decrease in the 18 to 64 age group, as an 
indirect consequence of the vaccination programme for children. 
The decrease in the penicillin resistance of pneumococcus continued, as did that of • 
resistance to macrolides and multiresistance.
The number of meningococcus infections was on a par with the previous year. • 
More than half of the cases in serogroup B were diagnosed in young children, 
whereas cases caused by groups C and Y were mainly detected in older age 
groups. No clusters of the disease were found.
Less than 500 cases of varicella virus findings were reported, on a par with the two • 
previous years. Childhood varicella or chicken pox is a very common disease, with 
an estimated 57,000 cases in Finland every year. It is mainly diagnosed clinically 
and, in the vast majority of cases, the disease does not even result in a laboratory 
sample being taken. 
The incidence of borrelia is highest in the autumn, from August to October. The • 
number of cases was equal to that of previous years.
The number of tick-borne encephalitis (TBE) cases remained unchanged in • 
comparison with previous years. The Raseborg region, coastal areas of Lake 
Lohjanjärvi, the sea coast in Kirkkonummi and the Jollas shore in Helsinki emerged 
as new potential areas of infection. 
Approximately a quarter more cases of Puumala virus were reported than in 2013. • 
The majority of patients were of working age.
A total of 30 people were exposed to rabies abroad, mainly in Thailand. Two thirds • 
of the cases were related to dog bites. 
Most malaria cases originated in Africa. More than half of the patients were • 
immigrants coming from a malarious area.
invasivE pnEumococcal 
disEasE (strEptococcus 
pnEumoniaE)
The reported number of invasive, severe cases of 
pneumococcal disease, in which the pathogen was 
identified in a blood or cerebrospinal fluid culture, 
was 703 (13/100,000; in 2013 723, 13/100,000). In 
addition, the number of cases reported on the basis 
of antigen or nucleic acid detection totalled 21. No 
serotype data is available for these cases and they are 
not included in the statistics below.
Children under the age of 5 accounted for 3.8% of 
the patients and over 65-year-olds for 50.4%. As 
before, the incidence was higher among men than 
among women (16 vs. 10/100,000). Regional varia-
tion between hospital districts was approximately tri-
ple (8–23/100,000), which may be due to differences 
in how actively blood cultures are taken. 
In 2014, 697 cases of pneumococcal disease con-
firmed by culture were serotyped. The National Insti-
tute for Health and Welfare did not obtain the strain 
of six cases confirmed by culture, and the serotype 
remained unknown for these. The cases were divided 
into 37 serotypes or serogroups. In addition, one un-
encapsulated strain was detected. The most common 
serotype, 3, caused almost one fifth (122; 17.3%) of 
all cases. The next most common serotypes were 19A 
(95; 13.5%) and 22F (71; 10.1%). These three were 
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Figure 15. Serotypes of Streptococcus pneumoniae findings in blood and cerebrospinal fluid 2014 (no. of cases).
The column ”Other” includes serotypes that caused fewer than 10 cases.  
PCV10 serotypes, green columns.
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 known
common, particularly in adults, and covered 41.0% 
of all cases. In comparison with the previous year, se-
rotypes 3 (2014: 122 vs. 2013: 88), 19A (95 vs. 68) 
and 23A (23 vs. 10) were the ones that became more 
frequent.
The 10-valent pneumococcal conjugate vaccine 
(PCV10) has been included in the basic vaccination 
programme for children since September 2010. Se-
vere pneumococcal diseases caused by serotypes in 
the PCV10 vaccine (1, 4, 5, 6B, 7F, 9V, 14, 18C, 
19F, 23F) have almost been eliminated in young chil-
dren and have continued to decrease, particularly in 
the 18 to 64 age group in 2014, compared to the 
years (2008–2009) which were prior to the introduc-
tion of the vaccine. This is an indirect consequence of 
the vaccination programme for children. In children 
under 2 years of age, two cases caused by PCV10 se-
rotypes were diagnosed. In addition, two other cases 
caused by PCV10 serotypes were found in children 
aged 2 and 3, vaccinated in accordance with the pro-
gramme. The number of cases caused by serotypes 
other than PCV10, including 19A, increased as in 
the two previous years, particularly in the oldest age 
group (65 and over). For more detailed statistics by 
age and serotype, please see the National Institute for 
Health and Welfare website. 
Antimicrobial sensitivity was determined for 716 
strains of invasive pneumococcus. Strains with re-
pcV10 vaccine serotypes non-vaccine serotypes un-
known
total
<2 2−4 5−17 18−64 65− total <2 2−4 5−17 18−64 65− total
2005 52 26 15 244 132 469 15 7 3 120 86 231 37 737
2006 67 26 16 227 160 496 14 5 3 106 102 230 22 748
2007 63 38 12 226 176 515 15 5 6 117 111 254 17 786
2008 49 26 18 288 198 579 14 6 4 173 119 316 31 926
2009 47 26 23 277 165 538 12 4 8 141 117 282 33 853
2010 51 35 11 246 166 509 8 5 5 150 124 292 32 833
2011 34 16 15 217 150 432 11 11 6 166 144 338 5 775
2012 8 15 7 188 149 367 7 2 8 172 191 380 3 750
2013 6 3 9 164 112 294 13 11 5 192 206 427 2 723
2014 2 3 8 99 93 205 11 11 10 203 257 492 6 703
Table 12. Streptococcus pneumoniae findings in blood and cerebrospinal fluid by age and vaccine serotype, 
2005–2014 (no. of cases). The column “Unknown” includes cases, whose strains the National Institute for Health 
and Welfare did not receive.
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duced susceptibility to penicillin (MIC > 0.06 mg/L) 
accounted for 15% of the strains, and two strains 
completely resistant to penicillin (MIC > 2 mg/L) 
were found. The percentage of macrolide-resistant 
strains continued to decrease; 15% of invasive pneu-
mococcal strains were resistant to erythromycin. 
Multiresistant strains (PEN IR–ERY R–TET R) ac-
counted for 2% of the strains. No strains resistant to 
levofloxacin (MIC > 2 mg/L) or ceftriaxon (MIC > 2 
mg/L) were found in 2014. The decrease detected in 
2013 in the percentage of penicillin resistant strains 
and those with lower susceptibility seems to be con-
tinuing. The decline in macrolide resistance and mul-
tiresistance continued further.
haEmophilus (haEmophilus 
influEnzaE)
A total of 59 infections were caused by the Haemophi-
lus influenzae bacterium and were diagnosed in blood 
or cerebrospinal fluid. This was somewhat above the 
average rate in recent years, but was clearly less than 
in the peak year 2012 (81). One third of cases (20, 
34%) were diagnosed in patients aged 75 or older. 
All cases were diagnosed through culture findings. 
The majority of these (48, 81%) were caused by un-
encapsulated strains of Haemophilus influenzae, as in 
earlier years. There were five cases caused by serotype 
b. Three of these were diagnosed in individuals of an 
age (11 months, 9 years and 18 years) that would 
have entitled them to receive the Hib vaccine as part 
of the national vaccination programme. The young-
est of these patients had been vaccinated accordingly, 
but had only received two doses. The second-young-
est had received all three doses and the oldest only 
one dose at the age of three. Serotype f caused disease 
in six individuals, three of them young children (8 
months, 12 months and 6 years) and three adults. No 
other serotypes were detected. 
Children born in 1985 or later have been given the 
Hib vaccine at their child care clinics. The vaccina-
tion programme has succeeded in reducing the num-
ber of serious diseases caused by bacteria of serotype 
b, and the circulation of bacteria within the popula-
tion, but cases may still occur in children with in-
complete vaccination coverage. Not only serotype 
b but other serotypes may cause severe infections in 
young children. The vaccine does not protect patients 
from other serotypes. 
cases reported  
to the nIdr
studied  
strains
erythromycin 
(r) (%)
penicillin (I+r) 
(%)
multidrug  
resistance (%)
1998 561 84 3,6 0 0
1999 568 471 5,9 7,2 0
2000 601 439 8 3,7 1,4
2001 658 360 18,8 7,5 5
2002 599 594 16,3 8 3,7
2003 721 739 21,9 12,7 5,7
2004 748 748 20,5 9,6 3,7
2005 737 731 20,5 9,6 4,4
2006 748 760 27,9 16,4 5,4
2007 786 794 23,2 14,4 3,5
2008 926 930 24,5 17,7 3,4
2009 853 848 28,4 19,9 4,7
2010 833 819 28,6 23,4 1,7
2011 775 780 26,8 21,9 2,8
2012 750 754 22,2 27,7 5
2013 723 668 16,8 18,7 4
2014 703 716 14,5 14,8 2,4
I – reduced susceptibility: R – resistant; Multidrug resistance – strains simultaneously resistant to penicillin (I+R), erythro-
mycin (R) and tetracycline (R)
Table 13. Antimicrobial resistance of Streptococcus pneumoniae findings in blood and cerebrospinal fluid, 
1998–2014 (no. of cases and %).
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Group a Group b Group c Group y Group W135 unknown total
2003 0 36 6 4 1 2 49
2004 0 28 5 6 0 2 41
2005 0 29 5 4 2 4 44
2006 0 33 1 3 0 3 40
2007 0 38 5 1 0 1 45
2008 0 18 8 1 0 1 28
2009 0 19 8 2 0 0 29
2010 0 14 4 13 1 3 35
2011 0 19 6 7 1 1 34
2012 0 17 3 8 1 4 33
2013 0 10 2 8 0 0 20
2014 0 7 5 5 1 3 21
Table 14. Meningococcal infections by serogroup, 2003–2014 (no. of cases).
mEningococcus (nEissEria 
mEningitidis)
In 2014, the number of meningococcus infections 
detected in blood or cerebrospinal fluid totalled 21 
(0.39/100,000), which is around the same as in 2013. 
Of these cases, 18 were diagnosed through a bacte-
rial culture finding and three through nucleic acid 
detection. All bacterial strains were serogrouped and 
genotyped: 7 (33%) were of serogroup B, 5 (24%) of 
serogroup C, 5 (24%) of serogroup Y and 1 (5%) of 
serogroup W. The serogroup remained unknown for 
three cases diagnosed through nucleic acid detection. 
One quarter (5, 24%) of the cases were diagnosed in 
0–4-year-olds and one half (10, 48%) in patients over 
30. More than half (57%) of the cases caused by sero-
group B were diagnosed in young children, whereas 
cases caused by groups C and Y were mainly detected 
in older age groups. No epidemics or disease clusters 
were detected.
The strains of group B were highly heterogeneous, 
having been divided on the basis of genotypes into 
seven types, while the strains of group Y were divided 
into four types. In group C, the strains were of two 
types, one responsible for three (C:P1.5,2:F3-3) and 
the other for two (C:P1.5-1,10-8:F3-6) cases, mainly 
in Southern Finland. The latter strain type has caused 
epidemics in Central Europe among sexual minori-
ties and reportedly has a higher than usual mortality 
rate. Both Finnish patients died. 
The incidence of serogroup B bacteria in particular 
has decreased in recent years. This declining trend has 
been witnessed in other industrialised countries and 
may be due not only to changes in treatment prac-
tices, such as the earlier administration of antibiotic 
drugs, but also to natural variation in strain types. 
For instance, with regard to serogroup B, certain hy-
pervirulent, previously common strain types such 
as B:P1.7-2,4:F1-5 have almost disappeared in re-
cent years, whereas the incidence of serogroup Y has 
slightly increased lately, as in other Nordic countries. 
In sporadic cases of meningococcus, all persons in 
close contact with the patient – except for health care 
personnel – should be given prophylactic medication 
and a vaccination, if infection with the strain in ques-
tion can be prevented by vaccination. Finland has 
vaccines against the meningococcus serotype groups 
A, C, Y and W. The Defence Forces are administer-
ing a quadrivalent polysaccharide vaccination to all 
recruits, but infections belonging to serogroup B are 
still being found among them, as the vaccine affords 
no protection from it. Conjugated meningococcus 
vaccines are mainly used in connection with epidem-
ics and travel. New vaccines against group B menin-
gococcus strains are entering the market.
mmr dIseases (measles, 
mumps, rubella)
In 2014, two cases of measles were reported, on a par 
with recent years, but clearly fewer than in the peak 
year of 2011 (27). One of the patients was an un-
vaccinated young person who had been travelling in 
Southeast Asia. The other patient, who had also been 
infected while travelling abroad, was a foreign-born 
adult whose vaccination coverage is unknown. 
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Figure 16. Borrelia cases by hospital district, 2014 (no. of cases/100,000).
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In 2014, two cases of mumps were reported, both in 
adults. One of the patients was a person of foreign or-
igin, who had visited the home country immediately 
before falling ill, and whose vaccination coverage is 
unknown. The other patient was a man born in Fin-
land. No precise information is available on the place 
of infection or possible vaccination status.
No cases of rubella were recorded in Finland in 
2014.
varicElla virus
The number of varicella findings reported to the Na-
tional Infectious Diseases Register was 476 in 2014 
(2013: 455), which corresponds to the level of the 
two previous years. Of these findings, 197 were di-
agnosed by antigen detection, 130 by nucleic acid 
detection and 165 by serological diagnostics. There 
were 54 (10.8%) reports based on a diagnosis from 
cerebrospinal fluid, involving the identification of a 
varicella nucleic acid in 49 cases, a varicella antigen in 
three cases and varicella antibodies in nine cases.
Infected patients came from all age groups, the young-
est being 2 and the oldest 90 years old. Childhood va-
ricella or chicken pox is a very common disease, with 
an estimated 57,000 cases in Finland every year. In 
most cases, it is diagnosed clinically and in the great 
majority of cases the disease does not even result in 
a laboratory sample being taken. In contrast, herpes 
zoster, or shingles, causes far more use of health care 
services, especially by the elderly, which can be seen 
in the age distribution of the virus findings. The in-
cidence was 8.8/100,000 on average, being highest 
in the over 70 age group: 15.8/100,000 in the 70 
to 74 age group and 15.9/100,000 in the over 75 
age group. Varicella vaccination is currently recom-
mended to everyone aged 13 or over who has not had 
chicken pox. Moreover, a vaccine for herpes zoster 
will become available in pharmacies in 2015.
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Place of acquisition
TBE virus found in ticks
Figure 17. Cases of TBE by location of acquisition, 2014, and TBE virus findings in ticks, 1996–2014.
borrElia (lymE disEasE)
In 2014, 1,679 cases of borrelia were reported, on a 
par with previous years (2013: 1,707; 2012: 1,587 
and 2011: 1,662). Of these reports, 37 were based 
on nucleic acid detection and 1,633 on a serologi-
cal test. Cases were reported in all parts of the coun-
try. The average incidence was 31/100,000, but there 
was considerable regional variation. As in previous 
years, the incidence was highest in the Åland Islands 
(1,449/100,000), the 413 cases diagnosed there ac-
counting for a quarter of all cases of borrelia in Fin-
land. As before, the frequency of borrelia was high-
est in the autumn, the majority of cases occurring 
from August to October. The majority of the patients 
(75%) were aged over 45; 53% of the patients were 
women.
tick-bornE EncEphalitis (tbE)
In 2014, 47 TBE antibody findings were reported to 
the National Infectious Diseases Register, similar to 
the figures for previous years. Positive TBE findings 
were reported between June and November, the larg-
est number being reported in July. Patients who con-
tracted TBE were aged between 15 and 83. 
In order to identify the place of acquisition, the Na-
tional Institute for Health and Welfare interviewed 
patients who had been diagnosed with TBE in 2014 
and/or studied their patient records. Three patients 
contracted TBE on Åland, 43 in mainland Finland 
and two in Estonia. All residents of Åland have been 
entitled to a TBE vaccination free of charge since 
2006. No cases of TBE were diagnosed in vaccinated 
Åland residents. 
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Some of the cases in mainland Finland originated in 
previously known TBE risk areas: the Turku archi-
pelago (13), of which eleven occurred in Parainen; 
the Lappeenranta region (8), of which three occurred 
in the Sammonlahti area; the Kemi region (3); the 
Raahe archipelago (1); the Kotka archipelago (4) and 
the Kuopio region (3). The Raasepori region (2), 
coastal areas of Lake Lohjanjärvi (2), the sea coast in 
Kirkkonummi (3) and the Jollas shore in Helsinki (2) 
emerged as new, potential areas of infection. In addi-
tion, one infection originated in Kiihtelysvaara in the 
Joensuu region. In addition to this year’s cases, previ-
ously identified places of infection include Närpiö, 
Maalahti and the Sipoo archipelago. 
As well as in Åland, the TBE virus was identified in 
ticks in the Turku archipelago and the Lappeenran-
ta region decades ago, and in collections performed 
in the following risk areas in recent years: Isosaari in 
Helsinki, the Kokkola archipelago and Maksniemi in 
Simo.
If a patient falls ill with meningitis or encephalitis 
between May and November, even if he or she has 
not noticed a tick bite TBE should be suspected, es-
pecially if the case occurs in a known high-risk area. 
Because new endemic TBE regions may continue to 
emerge, the possibility of TBE infection should be 
considered even beyond currently known risk areas.
puumala virus
In 2014, a total of 2,088 cases of Puumala virus infec-
tion were reported (38.5/100,000), more than in 2013 
(1,685). The incidence of the virus varies depending 
on the virus reservoir, i.e. the size of the bank vole 
population. Such variation usually follows a three-year 
cycle: two abundant winters are followed by a quieter 
year. The previous peaks occurred in 2002, 2005 and 
2008, with a slight increase also occurring in 2011. 
Of the patients, 58% were men, and most patients 
were of working age. One hundred (4.8%) cases oc-
Figure 18. Cases of Puumala virus by hospital district, 2014 (no. of cases per 100,000 population).
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curred in patients under 20 years of age. The inci-
dence was highest in the hospital districts of North 
Savo (137/100,000) and East Savo (127/100,000).
pogosta disEasE (sindbis 
virus)
In 2014, 32 cases of Pogosta disease, confirmed with 
antibody testing, were diagnosed in Finland, one 
third of the case count (99) being diagnosed in the 
previous year. The incidence was highest in the hos-
pital districts of South Savo (1.9/100,000), South 
Karelia and Central Finland (1.5/100,000, respec-
tively). Of the patients, 66% were of working age, 
59% women and 88% of the cases were diagnosed in 
August–September.
The Sindbis virus is principally borne by mosquito 
species prevalent in late summer. Temperatures in 
the early summer and rainfall and snowfall in the 
previous winter significantly affect the incidence of 
the virus. Waterway regulation, other local ecologi-
cal factors together with cyclical variation in available 
animal reservoirs (forest game birds) may also play a 
role in the cyclical incidence of the disease in Finland. 
Cases of Pogosta disease tend to cluster in the period 
from late July to September.
Sindbis virus infection is more common in Finland 
than elsewhere in the world. The virus has an incuba-
tion period of one week, after which the infection pres-
ents with a fever commonly accompanied by a rash and 
muscle and joint symptoms. Some patients may suffer 
from pain in the joints for years, and it is not always 
easy to associate the pain with Pogosta disease. Genetic 
factors probably influence both the risk of contracting 
the disease and the presentation of symptoms.
Pogosta disease has followed a regular seven-year cycle 
since 1974, except for in 2009. The epidemic peaked 
in 1981, 1995 and 2002; in 2009, however, only 106 
cases were reported (2/100,000).
tularEmia (francisElla 
tularEnsis)
At only 9, the reported number of tularemia cas-
es in 2014 was the lowest on record (incidence 
0.17/100,000). More than half of the cases (5/9) were 
diagnosed in September and the others individually in 
different months. The annual incidence of tularemia 
varies considerably (between 0.3 and 18/100,000) and 
local epidemics break out every few years, particularly 
in the regions of Ostrobothnia and Central Finland. 
rabiEs
Doctors are required to report cases where risk as-
sessment after exposure has led to the administration 
of a course of rabies vaccinations and possibly rabies 
immunoglobulin treatment. In 2014, 53 reports were 
made, fewer than in 2013 (88). The number of pa-
tients who had been exposed while travelling abroad 
was 28: eight in Thailand, four in Turkey, three in 
Russia and two in Estonia and Indonesia, respective-
ly. Other cases were individual cases of exposure in 
different countries. Almost two thirds of the cases of 
exposure abroad were related to a dog bite, and six 
(19%) to a monkey bite.
Exposure in Finland was reported in 25 cases, nine 
(41%) of which were related to bats and four (16%) 
to cat bites. Only one case of exposure associated with 
a dog bite was reported, while the corresponding fig-
ure for the previous year was eighteen. Two persons 
had been exposed to rabies bait vaccine. In addition, 
one exposure of a veterinarian at work and two sus-
pected clinical cases were reported. Of the remaining 
cases of exposure, all but one were associated with 
contact with wild animals.
continent country cases
Asia Pakistan 1
Thailand 3
Total 4
Africa Angola 1
Benin 1
Burkina Faso 2
Cameroon 5
Democratic Repub-
lic of the Congo
1
Gambia 2
Ghana 5
Kenya 3
Liberia 1
Malawi 2
Mozambique 1
Nigeria 7
Ivory Coast 2
Sierra Leone 2
Total 35
total 39
Table 15. Malaria cases in Finland in 2014 by country 
of acquisition.
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travEl-rElatEd infEctions
malaria
Malaria was diagnosed in 39 patients in Finland in 
2014. There were 32 cases of Plasmodium falciparum, 
plus one case of P. falciparum + P. ovale double infec-
tion, four of P. vivax, one P. ovale + P. vivax double 
infection and one case of P. malariae. Most infections 
were contracted in Africa (35 cases, or 90%), 27 (77%) 
in western Africa. All P. falciparum infections originat-
ed in Africa. One infection was acquired on the Indian 
subcontinent, and three P. vivax infections in South-
east Asia. Of these patients, eleven (28%) were native 
Finns who had been travelling in a malarious area for 
less than six months, one was a Finnish resident in a 
malarious area; 20 (51%) were immigrants from a ma-
larious area who had been visiting their home country, 
five were immigrants who had fallen ill immediately 
after their arrival in Finland, and two were visitors to 
Finland. The countries in which patients contracted 
malaria and the related risk groups remained approxi-
mately the same as in previous years. 
dengue fever
The annual number of dengue fever infections has 
varied between 35 and 90. In 2013, laboratories re-
ported 80 findings. The corresponding figure for 
2014 was 38, of which the majority (36/38) occurred 
in 15–59-year-olds. In addition, two cases were re-
ported in the 65 to 69 age group. Diagnoses were 
made around the year. No comprehensive data is 
available on the countries of acquisition. Four infec-
tions were reported as having been contracted in Af-
rica (Tanzania 2, Mozambique 1, Senegal 1), eight in 
Asia (Thailand, Cambodia, Malaysia and Singapore 
6, India 1, the Philippines 1), two in the Caribbean 
and Americas, and one in Tahiti. 
chikungunya
In 2014, laboratories reported four findings of Chi-
kungunya. In the previous year, there was one case. 
No comprehensive information is available on the 
countries of infection, but in 2014 more than a mil-
lion infections caused by the chikungunya virus were 
reported in the Caribbean and Americas. Outbreaks of 
epidemics were also reported in the Pacific islands. 
other travel-related infections
A significant percentage of the following infections are 
travel-related: legionella, salmonella, campylobacter, 
shigella, EHEC, hepatitis A, hepatitis B, gonorrhoea, 
syphilis, HIV and AIDS, carbapenem-resistant gram-
negative bacilli, MMR diseases and rabies. Data on 
the country of acquisition and mode of transmission 
is discussed separately for each of these diseases in the 
respective section of this report.
blood and cErEbrospinal 
fluid findings in childrEn
blood culture findings in children
In 2014, 446 cases of blood culture positive find-
ings in children under 15 years of age were report-
ed, which is slightly more than in the previous year. 
However, in comparison with recent years, the num-
ber has remained largely unchanged (in 2000−2013, 
570 on average, variation 426−686).
Less than half of the findings (234/446) were in ba-
bies under 12 months of age. Among infants, Staph-
ylococcus epidermidis and other coagulase-negative 
staphylococci caused 29% of blood culture positive 
infections (table 16). Although these bacteria belong 
to normal skin flora, they typically cause late-onset 
sepsis related to treatment in newborn babies in in-
tensive care. The second-most common cause (14% 
of the findings) was Streptococcus agalactiae (Group B 
streptococcus, GBS). This is typically contracted from 
the mother’s birth canal during labour and causes an 
infection (early-onset sepsis) in the newborn baby 
during its first days of life. Other common causes of 
infection were Escherichia coli (16% of the findings), 
Staphylococcus aureus (9%), Enterococcus faecalis (4%) 
and Streptococcus pneumoniae (3%). 
In the age group of 1 to 14 years, S. aureus (19%) was 
the most common cause of blood culture positive in-
fections in 2014 (table 17). As in 2013 and 2012, the 
incidence of S. pneumoniae (15%) was less than half 
of what it had been in previous years. A pneumococ-
cus vaccination for children was added to the nation-
al vaccination programme in 2010. Other common 
findings in this age group were coagulase-negative 
staphylococci (20%), E. coli (8%), Streptococcus pyo-
genes (7%) and the Streptococcus viridans group (3%).
cerebrospinal fluid findings in children
The number of bacterial and fungal findings related to 
children’s central nervous system infections remained 
at the same level as in the preceding years, as did the 
distribution of pathogens. The total number of cases 
reported in 2014 was 30 (the annual average from 
2000 to 2012 was 34, variation 22–57), of which 21 
were diagnosed in infants under 12 months old. The 
most common findings in the under 12 month age 
group were S. agalactiae, meningococcus, S. epider-
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midis and S. pneumoniae (Table 18); in the 1 to 14 
age group, S. pneumoniae and meningococcus were 
most common (Table 19). 
Gbs in newborns
Between 1995 and 2014, an average of 31 cases per 
year of early-onset GBS in newborns (diagnosed 
from blood and/or cerebrospinal fluid in children 
under the age of 7 days) were reported; the variation 
was 17 to 57 cases per year, and the incidence was 
0.3 to 1.0 per 1,000 live births. There were 17 cases 
in 2014 (0.3 cases per 1,000 live births). An average 
of 15 annual cases of late GBS disease cases detected 
at the age of more than 7 days have occurred during 
the fifteen-year surveillance period (range 6–24; inci-
dence 0.1–0.4 cases per 1,000 live births). There were 
15 cases in 2014 (0.3 cases per 1,000 live births).
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2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Staphylococcus epidermidis 61 110 98 100 92 87 64 70 76 50 62 46
Staphylococcus, other 
coagulase-negative
23 42 34 42 43 33 43 32 35 26 33 45
Escherichia coli 39 37 41 44 42 38 37 45 48 25 41 37
Streptococcus agalactiae 37 44 73 55 51 49 51 54 42 36 33 33
Staphylococcus aureus 23 32 32 37 25 23 22 24 21 31 22 20
Enterococcus faecalis 11 9 15 22 8 5 10 20 12 15 16 9
Streptococcus viridans group 14 16 12 9 9 8 9 16 13 6 8 8
Streptococcus pneumoniae 26 28 26 27 21 26 25 20 11 8 8 6
Klebsiella species 8 7 9 8 6 7 9 3 7 6 6 4
Neisseria meningitidis 2 5 3 2 3 3 5 4 1 2 4 3
Streptococcus pyogenes 1 3 0 0 3 2 4 2 0 6 1 2
Haemophilus influenzae 0 1 2 1 1 2 2 1 0 4 1 2
Enterobacter species 6 5 3 13 8 6 3 3 10 5 4 2
Streptococcus, other beta-
haemolytic
0 1 0 3 0 0 4 2 0 1 1 1
Enterococcus faecium 2 3 2 3 0 1 1 1 1 2 1 1
Listeria monocytogenes 0 0 0 2 1 0 1 1 0 1 1 1
Bacillus 1 2 2 1 4 4 2 1 1 1 1 1
Pseudomonas, other than 
aeruginosa
0 0 0 0 0 0 0 0 0 0 0 1
Yersinia enterocolitica 0 0 0 0 0 0 0 0 0 0 0 1
Salmonella, other than Typhi or 
Paratyphi
0 0 0 0 0 0 1 0 0 0 1 1
Streptococcus milleri group 0 0 0 1 0 0 0 0 0 0 0 0
Streptococcus bovis group 1 1 1 0 0 0 2 0 0 0 0 0
Enterococcus, other or 
unidentified
0 1 0 0 0 0 2 0 0 1 0 0
Propionibacterium species 0 0 0 0 1 0 0 0 1 0 0 0
Clostridium, other than 
perfringens 
0 1 0 1 0 0 0 0 0 1 0 0
Clostridium perfringens 0 0 1 0 0 0 0 0 0 0 0 0
Peptostreptococcus and 
Peptococcus 0 0 0 0 0 0 0 1 0 0 0 0
Stenotrophomonas maltophilia 1 0 1 0 2 0 2 2 0 0 0 0
Table 16. Blood culture findings in infants (under 12 months), 2003–2014 (no. of cases).
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2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Haemophilus, other than 
influenzae
0 0 1 1 0 1 0 0 1 0 0 0
Acinetobacter species 3 1 1 3 2 1 1 3 2 1 2 0
Veillonella species 0 0 0 1 0 0 0 0 0 0 0 0
Prevotella species 0 0 0 0 0 1 0 0 0 0 0 0
Bacteroides fragilis group 0 0 0 0 1 1 0 1 0 0 0 0
Pseudomonas aeruginosa 1 4 0 0 0 2 0 2 1 0 0 0
Serratia species 2 4 0 2 3 4 1 2 4 0 1 0
Proteus mirabilis 0 1 0 1 1 0 0 0 0 0 0 0
Citrobacter species 1 0 1 1 0 0 1 1 0 1 0 0
Other bacteria 8 6 3 8 7 7 5 5 9 8 3 6
bacteria, total 271 364 361 388 334 311 307 316 296 237 250 230
Candida albicans 2 3 4 4 2 3 1 2 1 1 2 3
Other candida species 2 0 1 0 2 1 0 0 1 2 0 1
fungi, total 4 3 5 4 4 4 1 2 2 3 2 4
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2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Staphylococcus aureus 48 58 41 37 42 40 36 43 42 47 48 40
Streptococcus pneumoniae 94 88 101 100 115 87 92 95 74 35 35 32
Staphylococcus epidermidis 30 25 41 40 33 22 31 37 29 17 25 28
Staphylococcus, other 
coagulase-negative
18 13 16 8 19 13 17 21 13 11 9 19
Escherichia coli 13 15 10 16 12 14 12 15 11 14 9 17
Streptococcus viridans group 13 18 24 25 21 21 25 37 23 27 27 14
Streptococcus pyogenes 12 4 0 9 13 11 11 6 15 9 8 14
Pseudomonas aeruginosa 6 3 6 3 2 1 3 7 4 3 4 9
Haemophilus influenzae 0 0 1 1 2 3 3 2 5 0 3 5
Bacillus 6 2 7 6 0 6 3 3 2 5 5 4
Citrobacter species 0 0 1 0 2 2 1 1 0 0 0 3
Streptococcus milleri group 0 0 3 2 0 2 2 2 1 1 0 2
Clostridium, other than 
perfringens
0 0 1 0 1 1 1 4 4 1 1 2
Streptococcus, other beta-
haemolytic
3 2 2 3 4 0 2 3 1 1 1 1
Enterococcus faecium 1 2 1 3 4 2 5 7 0 2 2 1
Enterococcus faecalis 2 2 4 2 6 6 4 6 3 5 1 1
Corynobacterium difteriae 0 0 0 0 0 0 0 0 0 0 0 1
Stenotrophomonas maltophilia 1 3 0 1 3 4 2 2 0 1 1 1
Neisseria meningitidis 5 2 7 5 3 4 0 6 2 2 3 1
Acinetobacter species 2 1 4 1 2 2 4 1 0 1 3 1
Fusobacterium species 0 1 2 3 5 5 1 1 1 1 1 1
Bacteroides fragilis group 0 2 3 0 0 0 1 0 2 0 0 1
Salmonella, other than Typhi or 
Paratyphi
1 1 1 2 5 2 0 6 2 3 4 1
Streptococcus bovis group 0 0 0 1 0 0 0 0 0 0 0 0
Streptococcus agalactiae 2 1 0 0 2 1 0 0 0 0 0 0
Enterococcus, other or 
unidentified
2 2 0 2 2 3 0 1 0 0 1 0
Propionibacterium species 1 0 0 0 0 0 0 0 0 2 1 0
Mycobacterium species 0 0 0 0 0 0 0 0 1 0 0 0
Table 17. Blood culture findings in children (aged 1 to 14), 2003–2014 (no. of cases).
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2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Listeria monocytogenes 1 0 0 0 0 0 0 0 0 0 1 0
Clostridium perfringens 1 0 0 1 2 0 1 1 0 0 0 0
Peptostreptococcus and 
Peptococcus 0 0 0 0 0 0 0 0 2 1 0 0
Haemophilus, other than 
influenzae
0 0 0 1 0 0 0 0 0 1 1 0
Veillonella species 0 0 0 1 0 0 0 1 0 0 0 0
Prevotella species 0 1 0 0 0 0 0 0 0 0 0 0
Pseudomonas, other than 
aeruginosa
0 0 1 0 1 0 3 0 0 0 0 0
Yersinia pseudotuberculosis 1 0 0 0 0 0 0 0 0 0 0 0
Serratia species 0 0 1 2 1 0 0 1 0 0 1 0
Salmonella Typhi 1 1 2 0 2 0 0 0 2 0 1 0
Proteus mirabilis 0 1 0 0 1 0 0 0 0 0 0 0
Klebsiella species 4 5 10 3 6 5 2 4 2 6 3 0
Enterobacter species 6 3 3 1 2 4 3 2 3 1 0 0
Other bacteria 8 14 22 14 15 10 13 24 11 14 9 12
bacteria, total 282 270 315 293 328 271 278 339 255 211 208 211
Candida albicans 1 0 1 1 0 2 0 2 0 1 2 1
Other candida species 2 1 0 3 3 1 0 0 3 0 1 0
fungi, total 3 1 3 4 3 3 0 2 3 1 3 1
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2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Streptococcus agalactiae 1 10 7 8 8 3 6 10 3 4 1 7
Streptococcus pneumoniae 6 8 4 1 4 3 2 3 2 1 2 2
Staphylococcus epidermidis 3 3 3 3 2 1 2 2 2 1 3 2
Neisseria meningitidis 2 4 0 1 2 1 2 1 0 3 3 2
Escherichia coli 1 2 0 2 1 1 1 2 1 0 0 2
Staphylococcus aureus 4 2 1 0 1 2 2 1 0 3 2 1
Propionibacterium species 1 1 0 0 0 0 0 0 0 0 0 1
Bacillus 0 0 0 1 0 0 0 0 0 0 0 1
Haemophilus influenzae 0 0 1 0 0 0 1 0 0 0 0 1
Citrobacter species 0 0 0 0 1 0 0 1 0 0 0 1
Streptococcus viridans group 1 0 0 0 0 0 2 0 1 0 0 0
Streptococcus pyogenes 0 0 0 0 0 0 1 0 0 0 0 0
Enterococcus faecium 0 0 0 1 0 0 0 0 0 0 0 0
Enterococcus faecalis 1 1 0 2 1 0 0 0 0 0 0 0
Staphylococcus, other 
coagulase-negative
1 2 1 0 0 4 1 0 0 2 0 0
Mycobacterium species 0 0 0 0 0 0 0 1 0 0 0 0
Acinetobacter species 0 0 0 1 0 0 0 0 0 0 0 0
Bacteroides, other than fragilis 
group
0 0 0 0 1 0 0 0 0 0 0 0
Serratia species 0 1 0 0 0 0 0 0 0 0 0 0
Klebsiella species 0 1 0 0 0 0 1 0 0 1 0 0
Enterobacter species 0 1 0 0 0 0 0 0 0 0 0 0
Other bacteria 1 1 0 0 0 0 1 0 0 0 1 1
bacteria, total 22 37 17 20 21 15 22 21 9 15 12 21
Candida albicans 0 0 0 0 0 0 1 0 0 0 0 0
fungi, total 0 0 0 0 0 0 1 0 0 0 0 0
Table 18. Cerebrospinal fluid culture findings in infants (under 12 months), 2003–2014 (no. of cases).
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Table 19. Cerebrospinal fluid culture findings in children (aged 1 to 14), 2003–2014 (no. of cases).
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Staphylococcus epidermidis 1 4 2 0 1 5 2 1 2 1 0 3
Streptococcus pneumoniae 10 2 1 5 5 2 4 2 3 0 4 2
Propionibacterium species 0 0 1 0 0 0 0 0 1 0 0 1
Neisseria meningitidis 4 4 5 7 6 3 2 3 4 2 3 1
Haemophilus influenzae 1 0 0 0 0 0 0 0 1 0 0 1
Streptococcus, other beta-
haemolytic
0 0 0 0 0 0 1 0 0 0 0 0
Streptococcus viridans group 1 1 0 2 0 0 0 0 0 0 0 0
Streptococcus pyogenes 0 0 0 0 0 0 0 0 0 1 0 0
Enterococcus faecium 0 1 0 0 0 0 0 0 0 0 0 0
Enterococcus faecalis 0 1 1 0 0 0 0 1 0 0 0 0
Staphylococcus, other 
coagulase-negative
2 2 2 0 0 0 1 0 0 0 1 0
Staphylococcus aureus 2 2 0 0 2 3 3 2 2 2 1 0
Mycobacterium species 1 0 0 0 0 0 0 0 0 0 0 0
Peptostreptococcus and 
Peptococcus 0 0 0 1 0 0 0 0 0 0 0 0
Stenotrophomonas maltophilia 1 0 0 0 0 0 0 0 0 0 0 0
Acinetobacter species 0 1 1 0 0 0 0 0 0 0 0 0
Bacteroides fragilis group 0 0 0 1 0 0 0 0 0 0 0 0
Klebsiella species 1 0 0 0 0 0 0 0 0 0 0 0
Enterobacter species 0 1 0 0 0 0 1 0 0 1 0 0
Other bacteria 0 0 1 0 0 2 1 1 0 0 1 1
bacteria, total 24 19 14 17 14 15 15 10 13 8 10 9
Candida albicans 0 1 0 0 0 0 0 0 0 1 0 0
fungi, total 0 1 0 0 0 0 0 0 0 1 0 0
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blood and cErEbrospinal 
fluid findings in adults
blood culture findings in adults
The total number of blood culture findings in adults 
in 2014 was 14,140 (2013: 11,658). The number 
of blood culture findings in the over 65 age group 
continued to grow, as previously, being 9,385 (2013: 
7,614). Gram-positive bacteria were more common 
in the working-age population (aged 15 to 64) and 
gram-negative bacteria among those aged 65 or more. 
Anaerobic bacteria constituted about 4% and fun-
gi 2% of all blood culture positive findings among 
adults.
In the working-age population, the most common 
bacterial finding was Escherichia coli, constituting al-
most a quarter of all cases (Table 20). The next most 
common findings were Staphylococcus aureus (17%), 
Streptococcus pneumoniae (7%), coagulase-negative 
staphylococci (8%), and Klebsiella species (5%).
E. coli was also the most common blood culture 
finding among patients aged 65 years or more, ac-
counting for over a third of all findings (Table 21). 
The next most common findings were Klebsiella spe-
cies (31%), S. aureus (11%) and coagulase-negative 
staphylococci (6%). 
cerebrospinal fluid findings in adults
In 2014, the total number of cerebrospinal fluid 
findings in adults was 132 (2000–2013 average 159, 
variation 111–180). Patients over the age of 65 ac-
counted for 30% of cases (39 out of 132).
Coagulase-negative staphylococcus was reported in 
21 per cent of cases involving working-age patients 
(Table 23). The most common actual pathogens 
were pneumococcus (18%) and S. aureus (10%). In 
patients aged 65 years or older, coagulase-negative 
staphylococcus accounted for one third of the find-
ings (Table 24). S. aureus (10%), Listeria monocyto-
genes (10%) and pneumococcus (3%) were the most 
commonly reported actual pathogens.
Group a streptococcus
In 2014, the number of invasive infections of Group 
A streptococcus (Streptococcus pyogenes) increased 
slightly in comparison with the previous year (2014: 
211 and 2013: 191). The prevalent emm types of 
Group A streptococci were the same as in previous 
years: emm28 and emm89 (Table 22). The increase in 
the macrolide-resistant type emm33 in 2013 (13; 7%) 
evened out in 2014 (12; 6%). The previously preva-
lent emm1 was not dominant in 2014: the decline 
that began in 2013 (18; 10%) continued in 2014 
(10; 5%). In addition to the aforementioned, the per-
centages of emm types emm4 (16; 8%), emm12 (11; 
5%) and emm66 (11; 5%) have remained elevated. 
As last year, the previously common emm84 was not 
detected at all. Although new emm types are continu-
ously emerging, the four most common emm types – 
emm28, emm89, emm4 and emm33 – accounted for 
66% of all emm types in 2014 (Table 22).
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Table 20. Blood culture findings in patients aged 15 to 64, 2003–2014 (no. of cases).
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Escherichia coli 644 707 779 797 837 871 884 930 934 942 952 1068
Staphylococcus aureus 472 486 457 565 544 526 541 579 641 617 645 800
Streptococcus pneumoniae 412 391 377 348 352 480 441 413 391 364 356 307
Staphylococcus epidermidis 286 294 286 281 265 278 312 263 223 182 210 240
Klebsiella species 122 150 183 144 157 185 186 207 164 217 220 218
Staphylococcus, other 
coagulase-negative
126 141 117 128 147 156 136 140 144 104 154 191
Streptococcus, other beta-
haemolytic
89 114 103 135 129 128 122 139 154 133 177 173
Bacteroides fragilis group 59 67 83 85 82 109 68 110 108 103 101 132
Streptococcus viridans group 120 136 141 130 115 137 144 147 153 149 149 129
Streptococcus milleri group 48 49 55 63 65 73 57 68 86 79 98 127
Streptococcus pyogenes 77 100 76 105 133 157 116 113 104 126 105 122
Enterococcus faecium 50 44 63 64 80 91 87 85 101 88 96 103
Enterococcus faecalis 84 80 100 83 105 83 107 86 97 102 83 99
Streptococcus agalactiae 68 64 99 76 83 96 95 110 75 89 96 88
Enterobacter species 60 62 49 77 70 69 81 99 86 96 90 85
Pseudomonas aeruginosa 85 58 88 62 72 74 78 91 92 79 91 74
Bacillus 22 15 18 22 24 25 21 32 34 27 42 60
Fusobacterium species 21 32 31 19 31 31 27 37 32 48 41 47
Clostridium, other than 
perfringens
14 12 29 25 18 24 29 23 20 32 29 43
Peptostreptococcus and 
Peptococcus 23 14 21 18 11 12 27 15 30 18 22 38
Citrobacter species 10 21 15 27 19 23 29 31 28 25 23 35
Campylobacter species 10 13 5 3 8 7 11 10 4 6 8 33
Serratia species 14 10 16 18 19 24 26 20 32 26 32 31
Salmonella, other than Typhi 
or Paratyphi
19 27 27 47 52 43 23 39 32 32 36 28
Proteus mirabilis 11 15 12 18 14 14 18 26 17 24 22 23
Listeria monocytogenes 12 7 10 10 9 8 9 15 7 17 11 18
Haemophilus influenzae 10 11 13 9 25 18 19 19 22 25 23 18
Stenotrophomonas maltophilia 6 12 12 7 5 15 12 12 9 7 14 16
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2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Capnocytophaga canimorsus 6 6 8 8 8 8 11 11 17 13 14 15
Acinetobacter species 10 16 16 10 21 13 18 14 21 14 11 15
Pseudomonas, other than 
aeruginosa
3 5 2 0 3 5 6 6 8 8 8 14
Clostridium perfringens 9 6 16 11 12 10 16 15 8 11 8 13
Prevotella species 11 11 15 11 8 13 13 15 16 16 10 12
Morganella morganii 4 4 3 8 7 14 8 6 8 7 18 12
Propionibacterium species 11 6 9 7 5 3 9 6 9 7 9 11
Neisseria meningitidis 18 19 16 20 21 9 13 14 17 12 5 10
Veillonella species 3 1 6 3 5 3 7 5 13 6 9 9
Bacteroides, other than fragilis 
group
0 5 2 4 3 5 10 1 7 3 7 8
Haemophilus, other than 
influenzae
0 5 6 3 3 3 0 2 3 10 5 6
Streptococcus bovis species 2 3 8 5 7 1 6 7 6 6 4 5
Enterococcus, other or 
unidentified
10 10 11 6 4 7 13 13 12 20 8 5
Salmonella Typhi 3 4 3 3 4 1 3 9 3 1 5 5
Proteus vulgaris 3 4 3 7 3 2 3 2 2 3 2 4
Mycobacterium species 5 0 3 4 5 2 2 2 4 3 8 3
Salmonella Paratyphi 3 8 2 3 6 6 3 3 1 3 1 2
Hafnia alvei 5 4 3 0 1 3 6 2 2 2 1 2
Yersinia pseudotuberculosis 1 1 0 0 0 1 0 0 0 1 1 1
Yersinia enterocolitica 0 0 1 0 1 0 1 1 0 0 0 0
Other bacteria 75 80 94 92 77 94 106 92 98 111 129 156
bacteria, total 3156 3330 3492 3571 3675 3960 3960 4085 4075 4014 4189 4654
Candida albicans 42 45 42 54 54 55 55 57 74 56 64 53
Other candida species 31 24 23 22 26 41 29 37 34 31 45 44
Other fungi 5 4 5 2 4 2 3 1 3 2 3 3
fungi, total 78 73 70 78 84 98 87 95 111 89 112 100
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Table 21. Blood culture findings in patients aged 65 or over, 2003–2014 (no. of cases).
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Escherichia coli 1313 1466 1624 1706 1760 1887 2054 2234 2479 2482 2874 3242
Staphylococcus aureus 483 483 483 601 568 671 692 729 780 797 876 1065
Klebsiella species 257 304 339 326 339 375 462 469 471 537 556 664
Streptococcus, other beta-
haemolytic
137 148 159 190 180 193 232 279 285 308 335 442
Staphylococcus epidermidis 231 254 284 264 275 299 271 326 316 300 344 366
Streptococcus pneumoniae 242 238 228 270 290 326 294 303 295 342 319 355
Enterococcus faecalis 146 192 183 202 220 217 222 229 275 286 301 345
Staphylococcus, other 
coagulase-negative
133 139 123 132 144 171 161 149 162 170 252 293
Bacteroides fragilis group 118 120 135 119 135 146 164 178 203 183 201 253
Pseudomonas aeruginosa 147 138 151 154 188 191 184 218 196 250 230 233
Enterococcus faecium 76 96 69 100 132 126 170 159 172 166 208 231
Enterobacter species 99 92 115 95 104 131 128 156 156 174 188 172
Streptococcus agalactiae 62 76 84 81 77 94 104 126 113 117 129 171
Streptococcus viridans group 101 102 101 110 113 140 135 132 168 172 190 161
Proteus mirabilis 62 80 57 68 92 99 102 106 98 130 116 156
Streptococcus milleri group 43 47 52 67 54 53 62 59 59 65 92 127
Citrobacter species 44 43 42 42 35 65 59 76 59 95 99 97
Streptococcus pyogenes 28 33 34 47 58 50 60 50 49 75 67 73
Serratia species 28 18 33 27 33 50 37 59 56 64 81 72
Clostridium, other than 
perfringens
18 26 29 30 33 30 39 44 38 45 39 60
Clostridium perfringens 27 32 29 36 39 34 49 40 51 56 34 57
Peptostreptococcus and 
Peptococcus 20 13 17 22 25 14 29 36 26 24 32 44
Listeria monocytogenes 19 18 20 25 26 26 20 44 31 36 45 43
Morganella morganii 10 14 21 14 26 11 18 29 30 16 30 39
Haemophilus influenzae 8 13 28 21 25 21 22 19 37 51 20 32
Bacillus 10 10 10 17 9 11 12 7 13 7 17 24
Fusobacterium species 7 13 10 9 15 10 8 17 14 19 18 22
Enterococcus, other or 
unidentified
19 16 17 19 15 24 20 25 33 34 17 21
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2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Streptococcus bovis group 9 20 12 17 17 15 25 14 13 21 29 19
Pseudomonas, other than 
aeruginosa
6 2 6 9 9 11 10 10 8 11 12 18
Acinetobacter species 8 13 10 18 11 12 16 16 17 19 21 16
Prevotella species 4 11 10 10 8 11 15 13 14 7 11 16
Proteus vulgaris 8 7 9 9 9 4 4 8 8 12 14 16
Salmonella, other than Typhi 
or Paratyphi
5 6 14 11 8 19 6 8 7 13 9 14
Campylobacter species 1 5 3 5 3 5 6 3 1 4 4 13
Propionibacterium species 4 8 13 9 4 5 9 10 13 6 7 12
Veillonella species 1 1 7 2 6 9 5 4 6 5 10 12
Bacteroides, other than 
fragilis group
5 8 4 3 5 8 13 8 8 16 12 10
Capnocytophaga canimorsus 1 1 1 4 2 3 2 2 6 7 12 9
Stenotrophomonas 
maltophilia 6 10 6 10 8 3 6 7 4 8 12 7
Haemophilus, other than 
influenzae
0 3 2 2 1 1 1 1 0 3 8 4
Hafnia alvei 1 4 4 3 6 8 7 6 1 8 6 4
Mycobacterium species 2 3 1 5 1 4 0 5 1 1 1 2
Neisseria meningitidis 4 3 2 5 2 6 6 6 6 5 4 2
Yersinia pseudotuberculosis 1 2 2 1 1 0 3 1 0 1 0 0
Yersinia enterocolitica 3 1 1 1 1 0 1 1 0 3 0 0
Salmonella Typhi 1 0 1 0 0 0 0 0 0 0 0 0
Other bacteria 61 74 90 87 80 119 121 113 133 142 186 232
bacteria, total 4019 4406 4675 5005 5192 5708 6066 6534 6911 7293 8068 9266
Candida albicans 63 50 40 54 56 66 49 93 65 70 77 72
Other candida species 41 28 25 21 26 26 42 31 47 39 60 44
Other fungi 6 5 4 5 7 8 3 3 4 1 3 0
fungi, total 110 83 69 80 89 100 94 127 116 110 140 116
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strains 
exam-
ined
emm1 emm28 emm84 emm89 emm33 other nt
2006 163 25 (15%) 33 (20%) 24 (15%) 11 (7%) 0 (0%) 59 (36%) 11 (7%)
2007 205 58 (28%) 26 (13%) 32 (16%) 12 (6%) 0 (0%) 72 (35%) 5 (2%)
2008 225 52 (23%) 47 (21%) 9 (4%) 10 (4%) 0 (0%) 102 (45%) 5 (2%)
2009 191 25 (13%) 56 (29%) 4 (2%) 29 (15%) 0 (0%) 74 (39%) 3 (2%)
2010 167 22 (13%) 37 (22%) 4 (2%) 26 (16%) 0 (0%) 77 (46%) 1 (<1%)
2011 163 25 (15%) 37 (23%) 4 (2%) 30 (18%) 0 (0%) 66 (40%) 1 (<1%)
2012 210 23 (11%) 66 (31%) 1 (<1%) 58 (28%) 5 (2%) 52 (25%) 5 (2%)
2013 176 18 (10%) 58 (33%) 0 (0%) 43 (24%) 13 (7%) 44 (25%) 0 (0%)
2014 205 10 (5%) 62 (30%) 0 (0%) 48 (23%) 12 (6%) 73 (36%) 0 (0%)
Table 22. Group A Streptococcus blood findings by emm-type, 2006–2014 (no. of cases and %).
The figures contain all variants of the emm-type in question.
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Table 23. Cerebrospinal fluid culture findings in patients aged 15 to 64, 2003–2014 (no. of cases).
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Staphylococcus epidermidis 22 24 34 32 17 26 18 11 10 21 12 17
Propionibacterium species 6 11 5 5 5 4 4 7 4 5 6 13
Streptococcus pneumoniae 26 21 15 17 14 26 20 15 12 19 13 11
Staphylococcus, other 
coagulase-negative
7 16 15 12 7 14 11 8 6 7 12 9
Staphylococcus aureus 10 17 10 9 16 13 13 12 20 15 11 9
Klebsiella species 1 1 3 2 1 4 2 1 2 0 1 5
Haemophilus influenzae 0 1 0 0 0 3 1 0 2 1 2 3
Streptococcus viridans group 2 1 5 7 2 1 2 2 4 2 2 2
Streptococcus pyogenes 1 0 0 1 0 2 2 1 1 0 0 2
Listeria monocytogenes 2 1 0 2 1 1 2 1 1 1 2 2
Pseudomonas aeruginosa 4 2 4 6 3 4 5 3 1 4 1 2
Enterobacter species 0 3 5 2 2 9 3 1 2 4 2 2
Streptococcus, other beta-
haemolytic
0 1 0 0 0 1 2 1 2 1 0 1
Streptococcus milleri group 0 0 0 0 0 1 0 0 0 0 0 1
Streptococcus agalactiae 0 2 0 1 5 2 0 2 0 1 1 1
Clostridium, other than 
perfringens
0 0 0 0 0 0 0 0 0 0 0 1
Neisseria meningitidis 14 11 15 20 16 4 9 6 7 6 1 1
Capnocytophaga canimorsus 0 0 1 0 0 0 1 0 0 1 0 1
Acinetobacter species 1 1 3 3 5 2 3 0 2 2 0 1
Bacteroides, other than 
fragilis group
0 0 0 0 0 0 0 0 0 0 0 1
Morganella morganii 0 0 0 0 0 0 0 0 0 0 0 1
Escherichia coli 0 0 7 4 3 3 4 1 1 2 1 1
Streptococcus bovis group 0 0 0 0 0 0 0 1 0 0 0 0
Enterococcus, other or 
unidentified
0 0 0 1 0 1 0 0 1 0 0 0
Enterococcus faecium 0 2 1 0 1 0 1 0 2 2 1 0
Enterococcus faecalis 3 5 2 4 5 4 3 4 3 3 0 0
Mycobacterium species 1 1 0 0 1 2 0 0 0 2 0 0
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2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Bacillus 0 0 3 6 4 3 0 0 0 2 0 0
Peptostreptococcus and 
Peptococcus 2 0 0 0 0 0 1 0 0 0 0 0
Stenotrophomonas 
maltophilia 0 1 0 0 1 0 0 0 1 0 0 0
Haemophilus, other than 
influenzae
0 0 0 0 1 0 0 0 2 0 0 0
Campylobacter species 0 0 1 0 0 0 0 0 0 0 1 0
Pseudomonas, other than 
aeruginosa
1 0 0 1 0 1 1 0 1 0 0 0
Serratia group 2 1 1 0 3 0 0 0 1 0 0 0
Salmonella, other than Typhi 
or Paratyphi
1 0 0 0 0 2 0 0 1 0 0 0
Proteus mirabilis 0 0 0 0 0 0 0 0 1 0 0 0
Citrobacter species 1 1 2 0 1 0 0 1 0 1 0 0
Other bacteria 2 2 2 4 3 2 4 0 1 2 1 5
bacteria, total 109 126 134 139 117 135 112 78 91 104 70 92
Other candida species 0 3 0 2 3 0 1 1 0 1 0 1
Candida albicans 1 2 1 0 1 0 0 0 0 1 0 0
fungi, total 1 5 1 2 4 0 1 1 0 2 0 1
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Table 24. Cerebrospinal fluid culture findings in patients aged 65 or over, 2003–2014 (no. of cases).
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Propionibacterium species 0 1 0 2 0 2 2 1 1 2 2 9
Staphylococcus epidermidis 5 6 10 9 12 10 6 3 4 7 8 8
Staphylococcus, other 
coagulase-negative
5 6 6 3 2 4 3 3 1 3 5 6
Staphylococcus aureus 7 7 5 3 2 3 6 5 5 2 10 4
Listeria monocytogenes 4 2 4 3 2 2 2 6 4 4 4 4
Enterococcus faecalis 3 0 2 2 3 0 1 0 0 2 0 2
Streptococcus pneumoniae 5 4 8 10 4 7 10 6 8 4 8 1
Streptococcus agalactiae 1 0 0 0 0 0 1 1 0 0 1 1
Mycobacterium species 4 1 4 0 0 1 1 0 1 0 0 1
Streptococcus, other beta-
haemolytic
2 0 1 1 0 0 1 0 0 0 1 0
Streptococcus viridans group 0 1 0 1 1 0 3 1 0 3 0 0
Streptococcus milleri group 0 0 0 0 0 0 1 0 0 0 0 0
Streptococcus bovis group 0 0 0 0 0 0 1 0 0 0 0 0
Enterococcus, other or 
unidentified
0 0 0 0 0 0 0 1 0 0 0 0
Enterococcus faecium 1 0 0 0 0 0 2 0 0 0 0 0
Bacillus 0 0 0 0 0 1 0 0 2 1 0 0
Peptostreptococcus and 
Peptococcus 1 0 0 0 0 0 0 0 0 1 0 0
Stenotrophomonas 
maltophilia 0 1 0 0 0 0 0 0 0 0 0 0
Neisseria meningitidis 1 1 2 1 0 1 0 2 0 1 1 0
Haemophilus influenzae 0 0 1 2 2 1 1 0 1 0 0 0
Acinetobacter species 1 0 0 1 1 0 0 0 0 0 0 0
Bacteroides fragilis group 0 0 0 0 0 0 1 0 0 0 0 0
Pseudomonas, other than 
aeruginosa
0 1 0 0 0 0 0 0 0 0 0 0
Pseudomonas aeruginosa 0 1 0 1 0 2 0 0 0 1 2 0
Proteus vulgaris 0 0 1 0 0 0 0 0 0 0 0 0
Proteus mirabilis 0 0 0 0 0 1 1 0 0 0 0 0
Klebsiella species 1 1 0 0 0 1 1 0 0 0 0 0
Escherichia coli 2 2 1 1 0 1 1 1 2 1 1 0
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2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Enterobacter species 0 1 0 0 1 0 0 1 1 1 1 0
Citrobacter species 0 0 0 0 0 0 0 0 1 0 1 0
Other bacteria 2 1 0 0 0 0 0 1 0 0 1 2
bacteria, total 45 38 45 40 30 37 45 32 31 33 46 38
Other candida species 0 1 0 0 0 0 1 0 1 0 0 1
Candida albicans 0 0 1 0 0 1 0 0 0 1 0 0
fungi, total 0 1 1 0 0 1 1 0 1 1 0 1
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Table 25. Blood culture findings in all age groups, 2003–2014 (no. of cases).
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Escherichia coli 2009 2225 2454 2563 2651 2810 2987 3224 3472 3463 3876 4364
Staphylococcus aureus 1026 1059 1013 1240 1179 1260 1291 1375 1484 1492 1591 1925
Klebsiella species 391 466 541 481 508 572 659 683 644 766 785 886
Streptococcus pneumoniae 774 745 732 745 778 919 852 831 771 749 718 700
Staphylococcus epidermidis 608 683 709 685 665 686 678 696 644 549 641 680
Streptococcus, other beta-
haemolytic
229 265 264 331 313 321 360 423 440 443 514 617
Staphylococcus, other 
coagulase-negative
300 335 290 310 353 373 357 342 354 311 448 548
Enterococcus faecalis 243 283 302 309 339 311 343 341 387 408 401 454
Bacteroides fragilis group 177 189 221 204 218 256 233 289 313 286 302 386
Enterococcus faecium 129 145 135 170 216 220 263 252 274 258 307 336
Pseudomonas aeruginosa 239 203 245 219 262 268 265 318 293 332 325 316
Streptococcus viridans group 248 272 278 274 258 306 313 332 357 354 374 312
Streptococcus agalactiae 169 185 256 212 213 240 250 290 230 242 258 292
Enterobacter species 171 162 170 186 184 210 215 260 255 276 282 259
Streptococcus milleri group 91 96 110 133 119 128 121 129 146 145 190 256
Streptococcus pyogenes 118 140 110 161 207 220 191 171 168 216 181 211
Proteus mirabilis 73 97 69 87 108 113 120 132 115 154 138 179
Citrobacter species 55 64 59 70 56 90 90 109 87 121 122 135
Clostridium, other than 
perfringens
32 39 59 56 52 55 69 71 62 79 69 105
Serratia group 44 32 50 49 56 78 64 82 92 90 115 103
Bacillus 39 29 37 46 37 46 38 43 50 40 65 89
Peptostreptococcus and 
Peptococcus 43 27 38 40 36 26 56 52 58 43 54 82
Clostridium perfringens 37 38 46 48 53 44 66 56 59 67 42 70
Fusobacterium species 28 46 43 31 51 46 36 55 47 68 60 70
Listeria monocytogenes 32 25 30 37 36 34 30 60 38 54 58 62
Haemophilus influenzae 18 25 44 32 53 44 46 41 64 80 47 57
Morganella morganii 14 18 24 22 33 25 26 35 38 23 48 51
Campylobacter species 11 18 8 8 11 12 17 13 5 10 12 46
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2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Salmonella, other than Typhi 
or Paratyphi
25 34 42 60 65 64 30 53 41 48 50 44
Pseudomonas, other than 
aeruginosa
9 7 9 9 13 16 19 16 16 19 20 33
Acinetobacter species 23 31 31 32 36 28 39 34 40 35 37 32
Prevotella species 15 23 25 21 16 25 28 28 30 23 21 28
Enterococcus, other or 
unidentified
31 29 28 27 21 34 35 39 45 55 26 26
Streptococcus bovis group 12 24 21 23 24 16 33 21 19 27 33 24
Stenotrophomonas 
maltophilia 14 25 19 18 18 22 22 23 13 16 27 24
Capnocytophaga canimorsus 7 7 9 12 10 11 13 13 23 20 26 24
Propionibacterium 16 14 22 16 10 8 18 16 23 15 17 23
Veillonella species 4 2 13 7 11 12 12 10 19 11 19 21
Proteus vulgaris 11 11 12 16 12 6 7 10 10 15 16 20
Bacteroides, other than 
fragilis group
5 13 6 7 8 13 23 9 15 19 19 18
Neisseria meningitidis 29 29 28 32 29 22 24 30 26 21 16 16
Haemophilus, other than 
influenzae
0 8 9 7 4 5 1 3 4 14 14 10
Hafnia alvei 6 8 7 3 7 11 13 8 3 10 7 6
Mycobacterium species 7 3 4 9 6 6 2 7 6 4 9 5
Salmonella Typhi 5 5 6 3 6 1 3 9 5 1 6 5
Salmonella Paratyphi 3 8 2 3 6 6 3 3 1 3 1 2
Corynobacterium diphteriae 0 0 0 0 0 0 0 0 0 0 0 1
Yersinia pseudotuberculosis 3 3 2 1 1 1 3 1 0 2 1 1
Yersinia enterocolitica 3 1 2 1 2 0 2 2 0 3 0 1
Other bacteria 152 174 209 201 179 230 245 234 251 275 327 406
bacteria, total 7728 8370 8843 9257 9529 10250 10611 11274 11537 11755 12715 14361
Candida albicans 108 98 87 113 112 126 105 154 140 128 145 129
Other candida species 76 53 49 46 57 69 71 68 85 72 106 89
Other fungi 11 9 11 7 11 10 6 4 7 3 6 3
fungi, total 195 160 147 166 180 205 182 226 232 203 257 221
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Table 26. Cerebrospinal fluid culture findings in all age groups, 2003–2014 (no. of cases).
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Staphylococcus epidermidis 31 37 49 44 32 42 28 17 18 30 23 30
Propionibacterium species 7 13 6 7 5 6 6 8 6 7 8 24
Streptococcus pneumoniae 47 35 28 33 27 38 36 26 25 24 27 16
Staphylococcus, other 
coagulase-negative
15 26 24 15 9 22 16 11 7 12 18 15
Staphylococcus aureus 23 28 16 12 21 21 24 20 27 22 24 14
Streptococcus agalactiae 2 12 7 9 13 5 7 13 3 5 3 9
Listeria monocytogenes 6 3 4 5 3 3 4 7 5 5 6 6
Haemophilus influenzae 1 1 2 2 2 4 3 0 4 1 2 5
Klebsiella species 3 3 3 2 1 5 4 1 2 1 1 5
Neisseria meningitidis 21 20 22 29 24 9 13 12 11 12 8 4
Escherichia coli 3 4 8 8 4 5 6 4 4 4 2 3
Streptococcus viridans group 4 3 5 10 3 1 7 3 5 5 2 2
Streptococcus pyogenes 1 0 0 1 0 2 3 1 1 1 0 2
Enterococcus faecalis 7 7 5 8 9 4 4 5 3 5 0 2
Pseudomonas aeruginosa 4 3 4 7 3 6 5 3 1 5 3 2
Enterobacter species 0 6 5 2 3 9 4 2 3 6 3 2
Streptococcus, other beta-
haemolytic
2 1 1 1 0 1 4 1 2 1 1 1
Streptococcus milleri group 0 0 0 0 0 1 1 0 0 0 0 1
Mycobacterium species 6 2 4 0 1 3 1 1 1 2 0 1
Clostridium, other than 
perfringens
0 0 0 0 0 0 0 0 0 0 0 1
Bacillus 0 0 3 7 4 4 0 0 2 3 0 1
Capnocytophaga canimorsus 0 0 1 0 0 0 1 0 0 1 0 1
Acinetobacter species 2 2 4 5 6 2 3 0 2 2 0 1
Bacteroides, other than 
fragilis species
0 0 0 0 1 0 0 0 0 0 0 1
Morganella morganii 0 0 0 0 0 0 0 0 0 0 0 1
Citrobacter species 1 1 2 0 2 0 0 2 1 1 1 1
Streptococcus bovis group 0 0 0 0 0 0 1 1 0 0 0 0
Enterococcus, other or 
unidentified
0 0 0 1 0 1 0 1 1 0 0 0
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2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Enterococcus faecium 1 3 1 1 1 0 3 0 2 2 1 0
Peptostreptococcus and 
Peptococcus 3 0 0 1 0 0 1 0 0 1 0 0
Stenotrophomonas 
maltophilia 1 2 0 0 1 0 0 0 1 0 0 0
Haemophilus, other than 
influenzae
0 0 0 0 1 0 0 0 2 0 0 0
Campylobacter species 0 0 1 0 0 0 0 0 0 0 1 0
Bacteroides fragilis group 0 0 0 1 0 0 1 0 0 0 0 0
Pseudomonas, other than 
aeruginosa
1 1 0 1 0 1 1 0 1 0 0 0
Serratia species 2 3 1 0 3 0 0 0 1 0 0 0
Salmonella, other than Typhi 
or Paratyphi
1 0 0 0 0 2 0 0 1 0 0 0
Proteus vulgaris 0 0 1 0 0 0 0 0 0 0 0 0
Proteus mirabilis 0 0 0 0 0 1 1 0 1 0 0 0
Other bacteria 5 4 3 4 3 4 6 2 1 2 4 9
bacteria, total 200 220 210 216 182 202 194 141 144 160 138 160
Other candida species 0 4 0 2 3 0 2 1 1 1 0 2
Candida albicans 1 3 2 0 1 1 1 0 0 3 0 0
fungi, total 1 7 2 2 4 1 3 1 1 4 0 2
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